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Organismal physiology is built upon the foundation of molecular processes. A central axis to maintaining
homeostasis in vivo is at the level of gene regulation. Tissue specific gene expression is created at the
level of epigenetics, where proteins guided by tissue specific DNA binding proteins create a chromatin
landscape for precise gene programs. Understanding these molecular processes is of vital importance to
understand the underpinning pathologies, such as metabolic syndrome, which are a growing medical
concern and require greater research efforts in order to tackle its challenges. A major epigenetic regulator
is histone deacetylase 3 (HDAC3), which is a core member of the nuclear receptor corepressor (NCoR)
complex. This ubiquitously expressed chromatin associated protein complex functions to repress target
gene transcription. Here we address the functional role of HDAC3 in β-cells of adult mice. An HDAC3 βcell specific knockout was generated using the MIP-CreERT transgenic mouse model and while HDAC3 βcell specific deletion did not increase total pancreatic insulin content, the mice demonstrated markedly
improved glucose tolerance and increased glucose-stimulated insulin secretion. Cistromic and
transcriptomic analyses of pancreatic islets revealed that HDAC3 regulated multiple genes that contribute
to glucose-stimulated insulin secretion. Furthermore, using mass spectrometry in conjunction of
cistromic analyses of interactors we have characterized the interactome of HDAC3 and detailed its
function in mammalian liver. We identified PROX1 as an abundant interactor which is corecruited with
HDAC3 by HNF4a in liver to corepress gene transcription important for maintenance of lipid homeostasis.
Lastly, as we continue to explore the protein-protein interaction networks of these critical factors, novel
tools are proving to be invaluable to their investigation. The advent of CRISPR-Cas9 genome editing has
allowed for reliable and simple design and generation of mouse models. Therefore we have employed this
technology to generate a variety of epitope tagged mouse models with the goal of comparing their tissue
specific interactomes. This body of work includes a wide breadth of biological techniques that have
succeeded in advancing knowledge of HDAC3 function in vivo, vital to our understanding of molecular
pathology in diabetes and obesity.
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ABSTRACT

BIOCHEMICAL AND FUNCTIONAL STUDIES OF HISTONE DEACETYLASE 3 IN
METABOLIC TISSUES
Jarrett Renn Remsberg
Dr. Mitchell A. Lazar

Organismal physiology is built upon the foundation of molecular processes. A central axis to
maintaining homeostasis in vivo is at the level of gene regulation. Tissue specific gene expression
is created at the level of epigenetics, where proteins guided by tissue specific DNA binding proteins
create a chromatin landscape for precise gene programs. Understanding these molecular
processes is of vital importance to understand the underpinning pathologies, such as metabolic
syndrome, which are a growing medical concern and require greater research efforts in order to
tackle its challenges. A major epigenetic regulator is histone deacetylase 3 (HDAC3), which is a
core member of the nuclear receptor corepressor (NCoR) complex. This ubiquitously expressed
chromatin associated protein complex functions to repress target gene transcription. Here we
address the functional role of HDAC3 in β-cells of adult mice. An HDAC3 β-cell specific knockout
was generated using the MIP-CreERT transgenic mouse model and while HDAC3 β-cell specific
deletion did not increase total pancreatic insulin content, the mice demonstrated markedly improved
glucose tolerance and increased glucose-stimulated insulin secretion. Cistromic and transcriptomic
analyses of pancreatic islets revealed that HDAC3 regulated multiple genes that contribute to
glucose-stimulated insulin secretion. Furthermore, using mass spectrometry in conjunction of
cistromic analyses of interactors we have characterized the interactome of HDAC3 and detailed its
function in mammalian liver. We identified PROX1 as an abundant interactor which is corecruited
with HDAC3 by HNF4 in liver to corepress gene transcription important for maintenance of lipid
homeostasis. Lastly, as we continue to explore the protein-protein interaction networks of these
critical factors, novel tools are proving to be invaluable to their investigation. The advent of
v

CRISPR-Cas9 genome editing has allowed for reliable and simple design and generation of mouse
models. Therefore we have employed this technology to generate a variety of epitope tagged
mouse models with the goal of comparing their tissue specific interactomes. This body of work
includes a wide breadth of biological techniques that have succeeded in advancing knowledge of
HDAC3 function in vivo, vital to our understanding of molecular pathology in diabetes and obesity.
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CHAPTER 1: General Introduction
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1.1 ENZYMATIC DEACETYLATION AND GENE EXPRESSION
A growing clinical concern in the developed world is the rampant increase in metabolic syndrome
and diet induced obesity (Cohen et al., 2011). These new medical obstacles are challenging in part
due to dysfunction of multiple tissues (Tilg et al., 2016). Therefore it is critical to understand the
molecular underpinnings of these pathologic states for the development of therapeutic
interventions. A central foundation to maintaining homeostasis in vivo and integrating changes in
the environment is at the level of gene regulation. In fact, a major class of proteins exist at this axis,
allowing cells to respond accordingly, termed nuclear receptors (Gronemeyer et al., 2004; Huang
et al., 2010). Indeed, as with many molecular mechanisms, these proteins do not work alone and
recruit multi-protein complexes to exert their function (Perissi et al., 2010). Nuclear receptors are
especially interesting because they can shift between recruiting corepressors or coactivators as a
function of ligand binding, a means to integrate metabolic signals from the environment.

A major mechanism by which nuclear receptor complexes regulate gene expression is in
manipulating the acetylation state of nucleosomes. Briefly, a nucleosome is the basic unit of
chromatin and how all eukaryotic genomic information is organized. This building block includes an
octomer of histone proteins wrapped in DNA, analogous to string on a bead. These beads then are
organized and regulated on a more macroscopic level (Luger et al., 2012). The amino (N-) terminal
‘tail’ of histones that are hyperacetylated no longer electrostatically attract the negatively charged
phosphate backbone of the DNA and therefore allow increased transcription, whereas deacetylated
histones will condense and prevent transcriptional machinery from progressing. The amino
terminus of histones is unstructured and the site of a huge variety of potential post translational
modifications (Zhao and Garcia, 2015). Differential modifications across the genome is one
mechanism by which organisms gain tissue specific gene expression profiles. While acetylation
has been known for many decades, only with the explosion of molecular biology advances have
we begun to understand its importance (Inoue and Fujimoto, 1969; Phillips, 1963). The
identification of the first histone deacetylases (HDACs) and subsequent structural studies provided
2

deeper insight into their function and importance in biology (Finnin et al., 1999; Taunton et al.,
1996). This diverse protein family has a wide breadth of functions across tissues, but at its core
has the same guiding principles for enzymatic deacetylation and repression of target genes through
chromatin compaction (Haberland et al., 2009; Lombardi et al., 2011; Struhl, 1998). However, it is
noteworthy that deacetylation can also occur on non-histone proteins (Yang and Seto, 2008). Here
we will focus on the histone deacetylase 3 (HDAC3) in the context of the nuclear receptor
corepressor complex function in gene regulation.

1.1a Coordination of residues for catalysis
At the core of all enzymes is the principle that they lower activation energy to facilitate a specific
reaction. The class I histone deacetylases are members of the metalloenzymes, meaning they
require the coordination of a metal ion to perform catalysis. We got our first glimpse to the structure
of a histone deacetylase from a homolog, histone deacetylase like protein (HDLP) from A. aeolicus
bound to an inhibitor (Finnin et al., 1999). This protein shares roughly 35% homology to HDAC1
and details the first HDAC catalytic core solved, but to the surprise of structural biologists the fold
was observed previously in arginase (Kanyo et al., 1996; Lombardi et al., 2011). The metal ion,
zinc is coordinated by histidine and aspartic acid residues (Figure 1.1A). This allows H135 to first
act as a general base, promoting nucleophilic attack of a coordinated water molecule to the
carbonyl of the acetylated lysine substrate (Figure 1.1B). During the formation of the tetrahedral
intermediate, Y298 and G143 are critical for stabilization. Indeed, mutating tyrosine 298 to
phenylalanine, which maintains a majority of the structural properties but lacks the hydroxyl to
perform hydrogen bonding, cripples the enzyme’s ability to perform catalysis (Dowling et al., 2008;
Sun et al., 2013; Vannini et al., 2007). Since the catalytic pocket and proposed mechanism are
conserved across HDACs, substrate specificity may come in the form of the surface residues
surrounding the catalytic pocket, or from protein-protein interactions. HDAC3 is unique among the
class I HDACs as it found stoichiometrically bound to the nuclear receptor corepressor (NCOR1)
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(Hörlein et al., 1995) or the silencing mediator for retinoic acid and thyroid hormone receptors
(SMRT or NCOR2) (Chen and Evans, 1995).

1.2 HDAC3 REQUIRES THE DEACETYLASE ACTIVATING DOMAIN
Histone deacetylases function in the context of large multiple-protein complexes to exert their
function (Joshi et al., 2013). HDAC3 in particular was identified as a core member of the SMRT
corepressor complex (Guenther et al., 2000). Both SMRT and NCOR1 are large proteins,
approximately 270 kilodaltons in mass, share a large degree of homology, and interestingly are
predicted to be mostly disordered with islands of structure (Watson et al., 2012a). This may allow
for the multiple distinct protein domains, mediating interaction and recruitment of complex members
and may be important for chromatin association or repression. One such structurally ordered region
interacts with HDAC3 and is termed the deacetylase activating domain (DAD) (Guenther et al.,
2001). Identified through truncation mutants, this region of SMRT shares a high degree of
conservation with NCOR1, which was also shown to bind HDAC3. Furthermore, HDAC3
synthesized in the absence of NCOR1 or SMRT will bind the TCP-1 ring complex (TRiC), an ATP
dependent chaperonin complex, suggesting HDAC3 may have difficulty folding and the DAD has a
chaperone like function stabilizing HDAC3 (Guenther et al., 2002). This interaction has been
extensively studied structurally (Abdelkarim et al., 2013; Millard et al., 2013a; Watson et al., 2012b,
2016), and recent in vivo studies have confirmed it is critical for proper gene regulation (Alenghat
et al., 2008; You et al., 2013). Also, HDAC3 relies on this interaction for recruitment to chromatin
(Sun et al., 2013). Moreover, the HDAC3-DAD interaction may be critical for the overall structural
integrity of the nuclear receptor corepressor (NCoR) complex (Ishizuka and Lazar, 2005). One of
the most important characteristics to this interaction, is that HDAC3 requires binding to DAD for
enzymatic activity.

4

1.2a HDAC3 enzymatic activity requires DAD
Thanks to the recent solving of the HDAC3-DAD crystal structure we can being to understand the
extent of this interaction and activation with atomic resolution (Watson et al., 2012b). In addition to
discovering a structural rearrangement of the DAD upon binding to HDAC3, the DAD makes
extensive intermolecular contacts along HDAC3’s surface. Surprisingly, electron density between
HDAC3 and DAD identified inositol tetraphosphate (IP4) present in the crystal (Figure 1.2A).
Indeed, without the ‘intermolecular glue’ of IP4, the HDAC3-DAD interaction would be challenged
electrostatically due to the cleft of basic residues on HDAC3 and DAD. Furthermore, the discovery
of IP4 regulation is not limited to HDAC3, and it present for other class I HDACs (Millard et al.,
2013a). IP4 makes various contacts with critical residues between HDAC3 and the DAD, including
Y470 of SMRT. Mutatgenesis demonstrated that this residue is critical for the binding and activation
of HDAC3 (Ishizuka and Lazar, 2005). Extending these studies in vivo have highlighted the
importance of HDAC3 activation by the DAD, and its contribution to gene expression (Alenghat et
al., 2008; You et al., 2013). However catalytic mutants such as Y298F which do not stabilize the
tetrahedral intermediate during deacetylation, can maintain a degree of proper gene expression
(Sun et al., 2013). Hinting at a possible structural role for repression of target gene expression.

1.3 THE NUCLEAR RECEPTOR COREPRESSOR COMPLEX
While studies predominantly focus on HDAC3 as the workhorse of the NCoR complex, there has
been significant gains in understanding the role of other members. Initially identified with HDAC3,
transducing β-like 1 (TBL1) and its homolog receptor 1 (TBL1R1) coimmunoprecipitated with SMRT
from HeLa cell extracts (Guenther et al., 2000; Yoon et al., 2003). The TBL1 proteins contain WD40
repeats and are highly conserved across species. As a core member of the NCoR complex, they
are essential for repression. This may be in part due to their interaction with hypoacetylated histone,
which may enhance the binding of the NCoR complex to target sites. However, some work
suggests the TBL1’s may have a more diverse function and are important for coregulatory
exchange (Perissi et al., 2004, 2008). As techniques for coimmunoprecipitation and mass
5

spectrometry improved, the G-protein pathway suppressor 2 (GPS2) was also identified as a
stoichiometric interactor (Zhang et al., 2002).

1.3a Architecture and organization of the complex
Indeed, biochemical techniques have addressed and narrowed the interaction domains of NCoR
complex members in an attempt to better understand its organization and mechanism of
repression. Interaction among the complex members TBL1X/R1 and GPS2 are localized to the Nterminus of NCOR1 and SMRT (Oberoi et al., 2011; Watson et al., 2012a). The ratio of complex
members on chromatin is not well understood, nor is the utilization of NCOR1 versus SMRT in vivo.
However, given structural insights into the individual components and interaction domains, we can
postulate. The TBL1 proteins are similar to TUP1 in their WD40 repeat domains, and both have
been shown to form tetramers. Perhaps this tetramerization is the basis for greater oligomerization
on chromatin to mediate repression, analogous to the proposed TUP1 mechanism (Matsumura et
al., 2012; Millard et al., 2013b). This suggests a conserved mechanism for higher order assembly
of corepressors on chromatin, and is in agreement with the original finding that the NCoR complex
is 1-2 megadoltons when isolated on gel filtration chromatography.

1.3b Binding of NCOR1/SMRT to nuclear receptors
Finally, to effectively repress target genes, the NCoR complex must be recruited to chromatin.
While it is suggested that TBL1’s interaction with histones can assist in this process through
interactions with histones, the complex achieves site specificity through sequence specific DNA
binding nuclear receptors. These interactions are mediated toward the C-terminus of NCOR1 and
SMRT and are termed receptor-interacting domains. Interestingly this conserved motif, the coRNR
box (IXXII) closely resembles the hydrophobic helix of the nuclear receptor (NR) box (LXXLL) used
by coactivators (Heery et al., 1997; Hu and Lazar, 1999; McInerney et al., 1998). These subtle but
distinct features contribute to the specificity of coregulators exchange on nuclear receptors as a
function of ligand binding, but the precise distribution and kinetics are not well understood (Millard
6

et al., 2013b; Nagy et al., 1999; Perissi et al., 1999). Due to the fact both corepressors and
coactivators interact with the same region on NRs in the ligand binding domain, these recruitment
events are mutually exclusive (Darimont et al., 1998; Feng, 1998; Nolte et al., 1998; Wang et al.,
2006; Xu et al., 2002).

1.4 NCOR COMPLEX IS CRITICAL FOR HOMEOSTATIC GENE REGULATION
The NCoR complex and its members has proven vital in maintaining proper gene expression. Use
of mouse genetics allows for interrogation of individual component roles in vivo and in different
tissues. As a ubiquitously expressed complex, tissue dependent binding and gene regulation would
come from the tissue specific expression of DNA binding proteins relying on the complex (Figure
1.3A). The HDAC3 containing NCoR complex can metaphorically be symbolized as an umbrella,
where its phenotypic effects encompass and are the sum of all of the DNA binding factors that
utilize the NCoR complex to repress their individual target gene programs. This becomes clear
when comparing the consequence of ablating HDAC3, NCOR1, or the nuclear receptor Rev-erb
from mouse liver as they all increase hepatic triglyceride content, but HDAC3 to the greatest extent
(Feng et al., 2011; Sun et al., 2012, 2013).

1.4a Tissue specific functions of the NCoR complex
Mutant and phenotypic studies of NCOR1 and SMTR has been extensively reviewed (Astapova,
2016) and highlight the diversity of functions attributed to the NCoR complex. Deletion of individual
components of the NCoR complex results in an increase in liver triglycerides (Kulozik et al., 2011;
Li et al., 2015; Shimizu et al., 2015; Sun et al., 2012), highlighting the importance of these proteins
acting together as a functional complex to regulate liver metabolic gene transcription.

Multiple tissue specific deletions of HDAC3 showcase the importance of this epigenomic modifying
enzyme (Alenghat et al., 2013; Hong et al., 2016; McGee-Lawrence et al., 2013; Mullican et al.,
2011; Singh et al., 2011; Sun et al., 2012). Liver, heart, and skeletal muscle ablations point HDAC3
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to focusing on metabolic gene expression, whereas studies in macrophages and preliminary β-cell
culture point toward inflammatory gene regulation (Chou et al., 2012; Lundh et al., 2012; Plaisance
et al., 2014).

1.5 HYPOTHESES AND OBJECTIVES
HDAC3 plays a clear and significant role of regulating gene expression within mammalian
metabolic organs. Preliminary studies suggest HDAC3 may play a pivotal role in the pancreatic βcell, but this has not been addressed in vivo with proper genetic manipulation. Moreover, where
the consequence of ablating HDAC3 in liver is well documented, fundamental questions remain.
The vast number of transcriptionally relevant complexes highlights the important roles proteinprotein interactions play in the control of gene expression and with regard to HDAC3, there are
important questions about which transcription factors recruit it to the genome, and which HDAC3associated proteins act as downstream effectors to impact lipid gene regulation and hepatic
steatosis.

We hypothesize that HDAC3 regulates glucose homeostasis in vivo and ablation may improve
insulin response in diet induced obesity. This is supported by a recent finding where treatment with
an HDAC3 selective inhibitor improved glycaemia and insulin secretion in a diabetic rat model
(Lundh et al., 2015). In Chapter 2, we apply mouse genetics to characterize and determine the
contribution of HDAC3 in pancreatic β-cell gene expression. We measure classic physiologic
parameters related to glucose homeostasis in mice lacking HDAC3 in their β-cells, in addition to
applying advanced genomic approaches to determine the altered transcriptional landscape and
HDAC3’s genomic occupancy.

Furthermore, we hypothesize that multiple nuclear receptors utilize the NCoR complex in
mammalian liver. To identify these interactors, in Chapter 3 we adopt a cross-linking mass
spectrometry

approaches

in

Chapter

3.

Traditional
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chromatographic

separation

and

immunoprecipitations have only identified core NCoR complex members. Therefore, we applied a
cross-linking set analogous to chromatin immunoprecipitation (ChIP) in order to capture lower
affinity or transit interactors of HDAC3 and the NCoR complex. Indeed, interrogation of cistromic
and ensemble mass spectrometry interaction data allow us to conclude there are multiple and
distinct factors utilizing the NCoR complex and HDAC3 to repress their target gene program in
mammalian liver. Also we identified PROX1 as a critical interactor, functioning to corepress gene
transcription important for maintenance of lipid homeostasis.

Finally, we extend these technical achievements to other proteins of interest and into tissues
beyond liver. In Chapter 4 we apply CRISPR-Cas9 genome editing to generate multiple epitope
tagged mouse models to address previously unattainable questions, including tissue specific
interactomes, interactomes across circadian time points, and overcoming technical limitations of
poor antibodies.

In summary, this body of work aims to further our understanding of HDAC3 in regulating tissue
specific gene expression and deepen our knowledge of its molecular mechanisms. Also, we utilize
recent advances in genome editing to expand on the foundations built and continue investigating
these proteins using mass spectrometry in tissues where current techniques and reagents
previously count not.

9

10

Figure 1.1 Crystal structure of HDAC3-DAD interaction and mechanism of catalysis. (A)
Overview of the HDAC3-DAD crystal structure (PDB 4A69), HDAC3 in green and the DAD of SMRT
in red. The zoomed insert is centered on the Zn2+ ion and residues involved in catalysis are shown
as stick models. (B) Proposed mechanism for deacetylation by HDACs, adopted from Lombardi et
al. to reflect HDAC3 residues. The general base promoted nucleophilic attack of the coordinated
water molecule on the carbonyl is shown.
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Figure 1.2 HDAC3 activation by DAD. (A) Crystal structure of HDAC3-DAD, highlighting the Y470
residue in the DAD critical for activation of HDAC3 in vivo and IP4 at the critical junction between
HDAC3 and the DAD of SMRT.
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Figure 1.3 NCoR mediated repression of target genes. (A) Schematic of NCoR complex
recruitment to chromatin by nuclear receptors (blue), deacetylation, and repression of gene
transcription.
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CHAPTER 2: Deletion of Histone Deacetylase 3 in Adult -cells Improves Glucose
Tolerance via Increased Insulin Secretion

Published in part in Molecular Metabolism, 2017; 6(1), 30-37.

The text, figures, and legends in this chapter were the work of Jarrett Renn Remsberg
with the following exceptions. The CVI Histology core performed the immunofluorescent
staining and the CHOP Pathology Core scanned insulin IHC. The Islet Core performed
islet isolations and ex vivo batch incubations. Manashree Damle and Zhenghui Li
performed ChIP-seq and RNA-seq bioinformatics analyses respectively. Ben Ediger,
Wesley Ho, Christopher Teng, and Cristina Lanzillotta provided technical assistance.
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2.1 ABSTRACT
Histone deacetylases are epigenetic regulators known to control gene transcription in a variety of
tissues. A member of this family, histone deacetylase 3 (HDAC3), has been shown to regulate
metabolic gene signatures in particular. Cell culture studies with HDAC-specific inhibitors and
siRNA suggest HDAC3 plays an important role in pancreatic β-cell function, but a recent genetic
study in mice has been contradictory. Here we address the functional role of HDAC3 in β-cells of
adult mice. An HDAC3 β-cell specific knockout was generated using the MIP-CreERT transgenic
mouse model. While HDAC3 β-cell specific deletion did not increase total pancreatic insulin
content, the mice demonstrated markedly improved glucose tolerance and increased glucosestimulated insulin secretion. Cistromic and transcriptomic analyses of pancreatic islets revealed
that HDAC3 regulated multiple genes that contribute to glucose-stimulated insulin secretion.

2.2 INTRODUCTION
2.2a Glucose homeostasis and diabetes mellitus
Glucose homeostasis is a tightly controlled process that is critical for maintaining normal
physiology. To achieve this balance, pancreatic endocrine cells secrete peptide hormones that act
on peripheral tissue to properly respond. Specifically, the role of the β-cells in the pancreas is to
secrete insulin in response to increase in plasma glucose levels.

This is first orchestrated by facilitated diffusion of glucose into pancreatic β-cells, mediated by the
glucose transporter, GLUT2 in mice. Inside the cell, this imported glucose is rapidly converted to
glucose-6-phosphate by glucokinase and proceeds through the glycolysis pathway. The
glucokinase enzyme (GCK) kinetics are remarkably well tuned to be sensitive at physiologic
increases in blood glucose concentration (Matschinsky, 2005). As a result of increased flux through
the glycolysis pathway and subsequent TCA cycle, cellular ATP/ADP ratio increases, causing KATP

channels close and depolarization. This in turn opens Ca2+ channels, causing an influx of Ca2+
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and leading to insulin granules fusing with the plasma membrane and being released into
circulation. This is the canonical pathway for glucose-stimulated insulin secretion, however
modulating or potentiating this response is of particular interest for therapeutic intervention.

Dysfunction of this glucose-stimulated insulin response can lead to diabetes mellitus. Type 1
diabetes mellitus is of growing clinical significance in the population and is hallmarked by
autoimmune recognition of the pancreatic β-cells (Patterson et al., 2009). This proinflammatory
environment created by the immune system leads to impaired function and death of the insulin
producing β-cells of the pancreas, whereas type 2 diabetes mellitus is characterized by insulin
resistance and failure of the insulin secreting β-cells, classically associated with obesity and lowgrade inflammation (Donath and Shoelson, 2011; Weir and Bonner-Weir, 2004). Growing evidence
suggests that changes in transcription, regulated by epigenetic changes may play a larger role in
the pathogenesis of both these diseases than previously appreciated (Bramswig and Kaestner,
2014).

2.2b Role of HDAC3 in pancreatic β-cells
Histone deacetylase 3 (HDAC3) is a member of the class I HDACs. It functions as part of multiprotein complexes that deacetylate histone tails, thereby modifying chromatin structure and
resulting in gene repression. HDAC3 has been shown to form stable complexes in vivo with, and
be activated by, the nuclear receptor corepressor (NCoR1) and the silencing mediator for retinoic
acid and thyroid hormone receptors (SMRT) (Guenther et al., 2001; Li et al., 2000). Class I HDACs
are ubiquitously expressed and have been implicated in regulation of metabolic gene signatures
(Sun et al., 2012). In the past several years, multiple studies of siRNA knockdown and
pharmacological inhibition of HDAC3 have suggested a role for HDAC3 in β-cells, with loss of
HDAC3 function protecting β-cells from cytokine-induced apoptosis and helping to maintain proper
glucose-stimulated insulin secretion (Chou et al., 2012; Lundh et al., 2012, 2015; Plaisance et al.,
2014; Wagner et al., 2016). Furthermore, an HDAC3-specific inhibitor was reported to improve
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glucose homeostasis and insulin secretion in a diabetic rat model (Lundh et al., 2015). These
studies presented an important question regarding HDAC3’s role in the pancreatic β-cell, precisely
the full extent of HDAC3’s function. To determine this physiologic role of HDAC3 in β-cells, we
applied mouse genetics to conditionally ablate HDAC3 in vivo. Here we demonstrate that the
deletion of HDAC3 in β-cells of adult male mice improves glucose tolerance by increasing insulin
secretion.

2.3 METHODS
2.3a Animal studies
The MIP-CreERT and HDAC3fl/fl lines have previously been described (Mullican et al., 2011;
Tamarina et al., 2014). Mice were maintained on a C57BL/6 background and normal chow unless
otherwise noted. Analyses were restricted to male mice. Tamoxifen (Sigma T5648) was dissolved
in corn oil at 20mg/mL and administrated at 2mg/day via gavage for five days. Animals were
assayed 2 weeks after tamoxifen induction. Intraperitoneal glucose tolerance tests (IPGTTs) were
performed as previously described (Ediger et al., 2014). Glucose-stimulated insulin secretion
(GSIS) assays were performed by administering mice a bolus of glucose (3g/kg) following a 16
hour fast. Plasma was separated using heparinized tubes, and insulin and C-peptide were
measured using ELISA kits (Crystal Chem #90080 and #90050, respectively). Total pancreatic
insulin and glucagon content were determined by radioimmunoassay (RIA) in which acid-ethanol
extractions were performed on whole pancreata (EMD Millipore). All the animal care and use
procedures followed the guidelines of the Institutional Animal Care and Use Committee of the
University of Pennsylvania in accordance with the guidelines of the US National Institutes of Health.

2.3b Immunohistochemistry and immunofluorescence
Pancreata were dissected, weighed, fixed in 10% formalin for 16 hours at 4°C, washed with PBS,
and embedded in paraffin. Tissue sections were stained as previously described using HDAC3 (H17

99 sc-11417), Insulin (ab7842), and Glucagon (N-17 sc-7780) antibodies (Ediger et al., 2014).
Insulin immunohistochemistry (IHC) was performed as previously described (Ediger et al., 2014).
Insulin signal was detected with Vectastain Elite ABC kit (standard; Vector, PK6100) and DAB
Peroxidase Substrate Kit (Vector, SK4100). To quantify islet mass, sections were digitally scanned
using an Aperio ScanScope CS2 and analyzed using ImageScope as previously described
(Oropeza et al., 2015).

2.3c Islet isolation and static incubations
Islets were isolated using the standard collagenase (EC 3.4.24.3 Serva, 17449) digestion protocol
as previously described (Doliba et al., 2015). For static incubations, islets were cultured for 3 days
and then transferred to KREBS buffer. An equal number of islets were glucose starved for 30
minutes and then glucose-stimulated for 40 minutes. Supernatants were collected and insulin
measurements performed by RIA.

2.3d RNA analysis
RNA was immediately extracted from isolated mouse islets two weeks after tamoxifen induction,
and quantitative reverse transcription-PCR (RT-PCR) was performed as described (Soccio et al.,
2015), using primers as indicated and normalized to Actb (Table 2.1). RNA-seq libraries were
generated using the Tru-seq kit (Illumina). Raw reads were aligned to mm9 reference genome
using Tophat version 2.1.0 and the parameters recommended by the original author (Trapnell et
al., 2012a); gene level quantification was performed by HTSeq using default parameters (Anders
et al., 2015), and differential expression analysis was performed using DESeq2 according to
original authors’ instructions (Love et al., 2014). RNA-seq datasets have been deposited at GEO.

2.3e ChIP-seq
Isolated mouse islets were washed with PBS, fixed with 1% formaldehyde at room temperature for
15 minutes, quenched with 125mM glycine for 5 minutes, and washed with PBS. Fixed islets were
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probe sonicated at 10W and 15W for 10 seconds on and 10 seconds off, twice. Sonicated islets
were lysed in RIPA buffer containing protease inhibitors and PSMF. ChIP was performed using
10μg HDAC3 antibody (ab7030) and protein A agarose. Cross links were reversed at 65°C
overnight and proteinase K digested, followed by phenol/chloroform isolation. Libraries were
prepared and sequenced as previously described (Zhang et al., 2015). Briefly, sequencing reads
of biological replicates were aligned to the mm9 genome using Bowtie v0.12.7 (Langmead et al.,
2009a). Duplicate reads were removed, and replicates were pooled using HOMER v4.7 (Heinz et
al., 2010). Genome browser tracks were generated, and peaks were called using HOMER with
default parameters and genomic DNA as input. Peaks from HDAC3fl/fl;Cre;Veh and HDAC3βKO
experiments were pooled, and an average profile was generated using HOMER. Additional analysis
was limited to peaks in HDAC3fl/fl;Cre;Veh greater than 1 read per million (RPM) and more than 4fold over HDAC3βKO. Distribution of peaks in the genome was found using HOMER. BEDTools
v2.26 was used to find peaks within 100kb of gene transcriptional start site (TSS) (Quinlan and
Hall, 2010a), and gene ontology analysis was performed on said peaks using GREAT v3.0 (McLean
et al., 2010). STRING analysis (Szklarczyk et al., 2015) was performed on transcription factors
identified in de novo motif analysis of HDAC3 peaks and expressed in RNA-seq with greater than
1 normalized read count. Transcription factors with known interactions with HDAC3 are presented
using Cytoscape v3.3.0. ChIP-seq datasets have been deposited at GEO.

2.4. RESULTS
2.4a Deletion of HDAC3 in β-cells does not significantly alter insulin content or
islet mass
To generate β-cell specific deletion of HDAC3 in C57BL/6 mice, HDAC3fl/fl mice were crossed with
mice expressing tamoxifen-inducible Cre recombinase under control of the mouse insulin 1 gene
promoter (MIP-CreERT) (Mullican et al., 2011; Tamarina et al., 2014). This Cre line has previously
been shown to be β-cell specific without recombination detected in the brain, unlike other putatively
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β-cell specific deletion models such as RIP-Cre (Magnuson and Osipovich, 2013). The HDAC3 βcell knockout (HDAC3βKO) was induced by 5 days of tamoxifen administration (2 mg/day) to 8
week old mice, and immunofluorescence studies confirmed the knockout of HDAC3 in insulinpositive islet cells when compared to HDAC3fl/fl mice expressing the MIP-CreERT transgene
administered corn oil vehicle (HDAC3fl/fl;Cre;Veh) two weeks after induction (Figure 2.1A). The
remaining islet HDAC3 signal was likely due to non-beta cells in the islet in addition to any β-cells
in which the knockout was incomplete. The β-cell deletion of HDAC3 was supported by quantitative
RT-PCR for Hdac3 transcript in freshly isolated islets (Figure 2.1B). There were no significant
differences in the total pancreatic insulin (Figure 2.1C) or glucagon content (Figure 2.1D) in the
HDAC3βKO mice. Islet architecture, assessed by insulin immunohistochemistry staining (Figure
2.1E), and islet mass (Figure 2.1F) were not appreciably altered in the HDAC3βKO mice.

2.4b HDAC3 ablation in β-cells of adult mice markedly improves glucose tolerance
To characterize the physiological consequences of the HDAC3βKO on β-cell function, we
determined their glucose tolerance.

Notably, there was a marked improvement in glucose

tolerance in HDAC3βKO mice during glucose challenge, as well as a modest fasting hypoglycemia.
(Figure 2.2A). The improvement in glucose tolerance was observed when comparing HDAC3βKO
animals to HDAC3fl/fl mice administered tamoxifen (HDAC3fl/fl;Tam) or to HDAC3fl/fl mice expressing
the MIP-CreERT administered corn oil vehicle (HDAC3fl/fl;Cre;Veh). This result is consistent with a
recent finding that the MIP-CreERT transgene does not impair or enhance glucose homeostasis
despite expressing human growth hormone (Oropeza et al., 2015). The HDAC3βKO did not
significantly alter body weight relative to control 6 weeks after induction of the knockout (Figure
2.2B). In addition, the improved glucose phenotype remains present over time, as mice assayed
6 weeks after knockout induction have significantly increased glucose tolerance (Figure 2.2C).
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2.4c Deletion of HDAC3 in β-cells of obese mice markedly improves glucose
tolerance
To determine if the loss of β-cell HDAC3 improves glucose tolerance in a model of obesity with
associated insulin resistance, mice were placed on high fat diet starting at 6 weeks of age.
Tamoxifen was administered at 18 weeks of age, and glucose tolerance was assessed at 20 weeks
of age. The knockout of HDAC3 in β-cells of obese mice did not alter body weight (Figure 2.3A)
but did result in significant improvement in glucose tolerance (Figure 2.3B). These data show that
acute deletion of HDAC3 has beneficial effects on glucose metabolism in the setting of diet-induced
obesity.

2.4d Improved glucose tolerance is a due to increased insulin secretion
To investigate the physiological basis of improved glucose tolerance in HDAC3βKO mice, we next
explored the effect of HDAC3 β-cell specific knockout on insulin secretion. It has been shown
previously that pharmacological HDAC3 inhibition or knockdown in cell culture can maintain
glucose-stimulated insulin secretion in the presence of cytokines (Chou et al., 2012; Lundh et al.,
2012; Wagner et al., 2016). Of note, HDAC3βKO mice on normal chow displayed significantly
increased circulating insulin after a 16 hour fast, as well as 3 minutes after a glucose challenge
(Figure 2.4A). This finding was corroborated by increased plasma C-peptide in the fasted and
glucose-stimulated conditions (Figure 2.4B). Further, in the setting of diet induced obesity,
glucose-stimulated insulin secretion was increased in HDAC3βKO mice (Figure 2.4C). These data
suggest that the loss of HDAC3 in β-cells led to increased insulin secretion and was responsible
for the improved glucose tolerance. To determine if the increased insulin secretion was a cellautonomous effect of β-cell depletion of HDAC3, glucose-stimulated insulin secretion was
examined ex vivo in isolated islets from mice on normal chow. Indeed, HDAC3βKO islets secreted
more insulin at lower glucose concentrations than control islets, whether normalized to the number
of islets (Figure 2.4D) or to total insulin content (Figure 2.4E), which was not significantly altered
by the loss of HDAC3 (Figure 2.4F). The enhanced insulin secretion at low glucose concentrations
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ex vivo is consistent with the increased basal insulin secretion observed during fasting of
HDAC3βKO mice, whereas the plateau of insulin secretion at high glucose for 40 minutes may not
be directly comparable to the in vivo GSIS measured 3 minutes after glucose challenge.

2.4e HDAC3 cistrome in isolated islets
To further investigate the means by which HDAC3 influences insulin secretion in vivo, we sought
to determine the HDAC3 cistrome in isolated islets. To achieve this goal, islets from
HDAC3fl/fl;Cre;Veh and HDAC3βKO were isolated and pooled for chromatin immunoprecipitation
with massively parallel DNA sequencing (ChIP-seq). There was robust enrichment for HDAC3 in
the HDAC3fl/fl;Cre;Veh control islets compared to HDAC3βKO (Figure 2.5A). We identified 9972
peaks in the HDAC3fl/fl;Cre;Veh control with greater than 1 read per million (RPM) and 4 fold over
input library; 8975 of these peaks had greater than 4 fold enrichment over the HDAC3βKO cistrome.
Consistent with HDAC3 cistromes from other tissues, the majority of genomic binding was intronic
or intergenic, with only a minority of binding sites at promoters or transcriptional start sites (TSS)
(Figure 2.5B) (Feng et al., 2011). Using the genomic regions enrichment of annotations tool
(GREAT), HDAC3 binding was found to be enriched at a variety of biological processes critical for
β-cell function, including endocrine development and regulation of insulin secretion (Figure 2.5C).
These data suggest that HDAC3 could be a critical transcriptional regulator of genes involved in βcell function and maintaining glucose homeostasis.

2.4f Transcriptome of HDAC3 β-cell KO reveals potential pathways contributing to
increased insulin secretion
To better understand the functional role of HDAC3 in the β-cell, we performed RNA-seq on islets
from HDAC3βKO mice in two separate cohorts of mice, one relative to HDAC3 fl/fl;Tam controls that
lack the MIP-CreERT transgene, and the other compared to the HDAC3fl/fl;Cre;Veh mice. Since the
two control models displayed indistinguishable glucose homeostasis, we reasoned that genes
significantly regulated in both experiments would shed light on the mechanisms by which HDAC3
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influences insulin secretion. This was particularly relevant given the recent report that Tph1 is
dramatically induced in the MIP-CreERT transgenic mouse, leading to increased islet serotonin
levels (Oropeza et al., 2015), which have been correlated with increased β-cell mass in pregnancy
(Kim et al., 2010). Using both control groups, transcriptomic analysis revealed 264 and 222
significantly up- and down-regulated genes in the HDAC3βKO islets (Figure 2.6A). Gene ontology
analysis of the up-regulated genes revealed amino acid activation, vesicle transport, anion
transport, and carbohydrate metabolism as significantly enriched processes (Figure 2.6B).
Quantitative RT-PCR confirmed RNA-seq results for many of the up-regulated transcripts in the
HDAC3βKO (Figure 2.6C).

2.4g Integrating transcriptomic and cistromic analyses of HDAC3 role in β-cells
Intersection of the islet transcriptomes and HDAC3 cistrome revealed that HDAC3 bound more
prevalently near genes that are subsequently up-regulated in the β-cell KO (Figure 2.7A). The
concordance of HDAC3 genomic binding with derepressed transcription in the HDAC3βKO islet is
exemplified at the Tmem40 locus (Figure 2.7B).

Genome-wide de novo analysis of DNA

sequences enriched under HDAC3 binding peaks revealed Forkhead, RFX5, PDX1, E-box, MADSbox, bZIP, nuclear receptor, SP1, and STAT motifs (Figure 2.7C). Intersection of these motifs with
of transcription factors expressed in the islet transcriptome revealed several signal-responsive
factors with the potential to function with HDAC3, including circadian proteins Rev-erb, ROR, and
CLOCK (Figure 2.7D), which may reflect the known role of HDAC3 in the circadian clock in other
tissues (Feng et al., 2011).

2.5 DISCUSSION
Our work demonstrates that HDAC3 in β-cells regulates insulin secretion and glucose metabolism.
HDAC3 is a critical epigenetic modifying enzyme and regulator of metabolic gene signatures.
Previous studies suggested a role for HDAC3 in mediating cytokine-induced apoptosis in cultured
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β-cell models and in a diabetic rat model, but the present study is the first to demonstrate that adult
mice lacking HDAC3 in their β-cells display markedly increased glucose clearance and tolerance.

The present studies, determining the physiological consequence of acute HDAC3 ablation in adult
mouse β-cells, suggest that HDAC3 plays an important role in modulating insulin secretion in
normal conditions as well as in the setting of diet-induced obesity. While these conclusions are
consistent with the beneficial result of HDAC3 specific inhibition in a diabetic rat model (Lundh et
al., 2015), they are contrary to those of a recent report where HDAC3 ablation was generated using
RIP-Cre (Chen et al., 2016). A major concern about the RIP-Cre model is that it has been shown
to produce off-target tissue recombination, particularly in the brain, where HDAC3 has been shown
to have important effects on behavior (McQuown et al., 2011; Nott et al., 2016; Rogge et al., 2013).
Also, the RIP-Cre model is not inducible; therefore, the effects in β-cells may emphasize the role
of HDAC3 in development rather than in the mature adult pancreas. Indeed, our cistromic results
suggest that HDAC3 genomic binding is enriched near genes involved in endocrine development,
and two genes upregulated in the HDAC3βKO, Rgs8 and Rgs16, have been shown to be
dynamically regulated in the developing pancreas (Villasenor et al., 2010). Nevertheless, the MIPCreERT model that we have used to delete HDAC3 avoids the problem of brain expression and
clearly demonstrates an inhibitory role of HDAC3 on insulin secretion from adult β-cells ex vivo and
in vivo.

We have identified a number of genes controlled by HDAC3 in β-cells with known or plausible roles
in glucose-stimulated insulin secretion. Among these are the organic anion transporters Slco1a5
and Slco1a6. Intriguingly, the Slco1a6 gene locus has been identified as an important quantitative
trait locus (QTL) in β-cells, regulating gene transcription by altering transport of bile acids in islets
(Tian et al., 2015). Notably, bile acids have been shown to potentiate glucose-stimulated insulin
secretion (Düfer et al., 2012). In addition to these transporters, Rgs16 was shown to be regulated,
which has been shown to increase glucose-stimulated insulin secretion (Vivot et al., 2016).
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Furthermore, S100a4 and its paralog S100a6 are identified as up-regulated in the HDAC3βKO
RNA-seq analysis. These genes are defined to be calcium binding proteins, and S100a6, also
known as Calcyclin, has been shown to potentiate Ca2+ stimulated insulin release (Okazaki et al.,
1994).

In silico analysis of the HDAC3 binding sites in islets suggested a potential role of several signal
responsive transcription factors including STAT and bZip family members, as well as components
of the circadian clock. Although highly speculative, the latter is intriguing given the known role of
the molecular clock in controlling β-cell functions (Lee et al., 2015; Perelis et al., 2015).
Interestingly, we did not detect an increase in insulin gene transcription in HDAC3βKO islets (data
not shown). Although this is consistent with the physiologic data presented here, it is worth noting
that a previous study using the pan-HDAC inhibitor Trichostain A (TSA) increased insulin gene
transcription (Mosley and Özcan, 2003). However, this drug inhibits all class 1 HDACs and thus
the present results suggest that other HDACs and/or other targets are responsible for the effects
of TSA in β-cells.

In summary, we have described the physiological role of HDAC3 in adult mouse β-cells and
identified several target genes that may in combination act to increase glucose-stimulated insulin
secretion in vivo. Thus, HDAC3 is a critical regulator of gene transcription in β-cells and, as a
druggable enzyme that modulates the epigenome, a potential therapeutic target to improve glucose
homeostasis, especially in the setting of diet-induced obesity and metabolic stress.
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Figure 2.1 HDAC3 β-cell KO does not increase insulin content or islet mass. (A) Coimmunofluorescence for HDAC3, Insulin, and Glucagon (20X). (B) Quantitative RT-PCR of freshly
isolated islets (n=5). (C, D) Total pancreatic insulin and glucagon content normalized to pancreatic
weight (n=4-6). (E) Insulin immunohistochemistry (IHC) staining (20X). (F) β-cell mass quantified
from insulin IHC staining (n=4). All error bars, s.e.m. (t-test, *p<0.001).
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Figure 2.2 Deletion of HDAC3 in β-cells of adult mice markedly improves glucose tolerance.
(A) Intraperitoneal glucose tolerance test (IPGTT) of mice on normal chow (NC) at 10 weeks of
age,

2

weeks

after

tamoxifen

administration,

2g/kg

glucose

(n=5,

t-test

compares

HDAC3fl/fl;Cre;Veh and HDAC3βKO). (B) Weight of mice on NC 6 weeks after tamoxifen induction
of KO. (C) IPGTT 6 weeks after KO induction (n=6-11). All error bars, s.e.m. (t-test, *p<0.05,
**p<0.01, ***p<0.001).
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Figure 2.3 HDAC3 β-cell KO improves glucose tolerance in the setting of diet-induced
obesity. (A) Body weights of mice on high fat diet (HFD). (B) IPGTT in mice after 14 weeks high
fat diet and 2 weeks after tamoxifen administration, 1g/kg glucose (n=5). All error bars, s.e.m. (ttest, *p<0.01).
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Figure 2.4 HDAC3 β-cell KO mice have increased insulin secretion. (A, B) Plasma insulin and
C-peptide of mice on normal chow after a 16 hour fast, and 3 minutes after intraperitoneal glucose
injection (3g/kg) (n=14). (C) Plasma insulin in mice on HFD for 15 weeks after a 16 hour fast, and
3 minutes after intraperitoneal glucose injection (3g/kg) (n=5). (D, E, F) Glucose-stimulated insulin
secretion (GSIS) ex vivo from isolated islets and corresponding total insulin content (n=5-9). All
error bars, s.e.m. (t-test, *p<0.05, **p<0.01, ***p<0.001).
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Figure 2.5 HDAC3 cistrome in isolated islets. (A) Average profile of HDAC3 binding in
HDAC3fl/fl;Cre;Veh and HDAC3βKO. (B) Distribution of HDAC3 genomic binding relative to known
genes. (C) GREAT analysis of HDAC3fl/fl;Cre;Veh specific peaks filtered against HDAC3βKO.
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Figure 2.6 RNA-seq analysis of HDAC3βKO compared to HDAC3fl/fl;Cre;Veh and
HDAC3fl/fl;Tam mice. (A) Scatter plot of log2 fold change from two separate RNA-seq experiments.
Red dots are significant (FDR<0.1) in both experiments and up-regulated 1.5 fold or greater in
either HDAC3βKO. Blue dots are significant (FDR<0.1) in both experiments and down-regulated
1.5 fold or greater in either HDAC3βKO. (B) Gene ontology (GO) biological process enrichment
results using 264 upregulated genes and 222 downregulated genes. Only significantly enriched
(p<0.05) terms are shown. For each terms, the numbers of the genes that contribute to the
enrichment is labeled. (C) Quantitative RT-PCR confirming significant upregulation of transcripts
from RNA-seq in the HDAC3βKO (n=5) (All error bars, s.e.m., t-test, *p<0.05, **p<0.01).
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Figure 2.7 HDAC3 cistromic analysis suggests multiple β-cell lineage factors utilize the
NCoR complex. (A) HDAC3 peak frequency within 100kb of gene TSS from RNA-seq analysis
(Mann-Whitney-Wilcoxon test, *p<0.05, **p<0.0001). (B) Genome-browser view of ChIP-seq and
RNA-seq tracks of the Tmem40 gene. (C) De novo motif analysis at HDAC3 binding sites genomewide using HOMER. Motifs with p-value<1e-150 or known interactions are shown. (D) STRING
analysis of transcription factors identified by de novo motif analysis of HDAC3 peaks. Transcription
factor families are denoted by different colors.
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Table 2.1 List of primers for quantitative RT-PCR gene expression.
Gene

Forward Primer

Reverse Primer

Hdac3

TTGGTATCCTGGAGCTGCTT

GACCCGGTCAGTGAGGTAGA

Tmem40

ACAGGGAAACGGAAGATCAC

AGGAGGAAGAGGAGGAAGAAG

Rgs8

AGGTCAACTGCAAAGCTAGTC

CAAAACAAGTCAGGGATGGC

Rgs16

ATCTTTGACGAGTACATCCGC

TCCTTCTCCATCAATGTGCG

Slco1a5

CTGAGGTGTATCAAGTCTGAAGAG

AGAGTTCCCCAATGTAAGCAG

Slco1a6

TTGTGCAGTTATGGGCCTAG

GGCTTTAAGGTCTGGGATCTG

Foxa3

CAGTGAAGATGGAGGCTCATG

GAGTGGGTTCAAGGTCATGTAG

S100a4

CAGCAACAGGGACAATGAAG

ACTACACCCCAACACTTCATC

Mars

TGGTCTTTCCGTGTTCAGTC

GTCTCCAAACACTCCTATGCC

Car8

TTGAAGGCTGTGACTGAGATC

CTGCAAGGTGGGATAGTAAGAG

Aldob

CACCGATTTCCAGCCCTC

GTTCTCCACCTTTATCCTTTGC

Actb

ACCGTGAAAAGATGACCCAG

GAGCATAGCCCTCGTAGATG
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CHAPTER 3: An HDAC3-PROX1 Corepressor Module Acts on HNF4 to Control
Hepatic Triglycerides

The text, figures, and legends in this chapter were the work of Jarrett Renn Remsberg
with the following exceptions. Sean Armour contributed equally to the manuscript and
generated ChIP-qPCR and ChIP-seq libraries. Manashree Damle and Zhenghui Li
performed ChIP-seq and RNA-seq bioinformatics analyses respectively. The Molecular
Pathology and Imagine Core performed histology. Wesley Ho provided mouse husbandry
and technical assistance. Simone Sidoli provided mass spectrometry technical
assistance.
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3.1 ABSTRACT
The histone deacetylase HDAC3 is a critical mediator of hepatic lipid metabolism, and liver-specific
deletion of HDAC3 leads to fatty liver. To elucidate the underlying mechanism we developed a
method of cross-linking followed by mass spectrometry to define a high-confidence HDAC3
interactome in vivo that includes the canonical NCoR-HDAC3 complex as well as Prospero-related
homeobox 1 protein (PROX1). HDAC3 and PROX1 co-localize extensively on the mouse liver
genome, and are co-recruited by Hepatocyte Nuclear Factor 4 (HNF4). The HDAC3-PROX1
module controls the expression of a gene program regulating lipid homeostasis, and hepaticspecific ablation of either component increases triglyceride content in liver. These findings
underscore the importance of specific combinations of transcription factors and coregulators in the
fine tuning of organismal metabolism.

3.2 INTRODUCTION
Hepatic lipid homeostasis is critical for the maintenance of normal liver physiology and organismal
metabolism. Lipid composition and accumulation in the liver is controlled by a complex network of
interconnected metabolic pathways such as lipid synthesis, lipolysis, β-oxidation, secretion, and
storage, and the dysregulation of even one of these pathways can lead to lipid accumulation in
liver, or hepatic steatosis (Browning and Horton, 2004; Tilg et al., 2016). Non-alcoholic fatty liver
disease (NAFLD), defined by excess fat in the liver, is of growing clinical relevance in industrialized
countries and is a major risk factor for the development of non-alcoholic steatohepatitis, liver
fibrosis and cirrhosis (Cohen et al., 2011). In addition, NAFLD has been linked to cardiovascular
disease, metabolic syndrome, insulin resistance and hepatocellular carcinoma (Tilg et al., 2016).
Thus, the mechanisms governing liver lipid homeostasis are of broad importance to understanding
the development of NAFLD and to identify targets for therapeutic intervention.

35

These pathways of lipid homeostasis are regulated in liver by a host of transcription factors
including the nuclear receptors HNF4(Hayhurst et al., 2001; Sladek et al., 1990), Rev-erb (Feng
et al., 2011), LXRs (Calkin and Tontonoz, 2012), PPARs (Gross et al., 2016), and the E-box binding
proteins SREBP and ChREBP (Xu et al., 2013) amongst others. In addition to these sequencespecific DNA binding factors, numerous cofactors and coregulators have been shown to influence
the expression of genes controlling lipid metabolism (Wang et al., 2015). Previous work has
demonstrated histone deacetylase 3 (HDAC3) to be an important epigenomic coregulator in liver
(Feng et al., 2011; Knutson et al., 2008), and deletion of HDAC3 in adult liver results in remarkable
hepatic steatosis (Sun et al., 2012). However, the fundamental mechanisms of how HDAC3
controls metabolic gene transcription in liver are not completely understood.

HDAC3 is unique among the class I histone deacetylases as it requires binding to the nuclear
receptor corepressor (NCOR1) (Hörlein et al., 1995) or the silencing mediator for retinoic acid and
thyroid hormone receptors (SMRT or NCOR2) (Chen and Evans, 1995) for its enzymatic
activity(Guenther et al., 2001; Wen et al., 2000; You et al., 2013). Together with transducing β–like
1X-linked and receptor 1 (TBL1X and TBL1XR1) (Guenther et al., 2000) and the G-protein
suppressor 2 (GPS2) (Zhang et al., 2002), these proteins form the core of the NCoR transcriptional
repressor complex (Lazar, 2003). The NCoR complex has been shown to be a major corepressor
complex for the nuclear receptor family of transcription factors (Chen and Evans, 1995; Hörlein et
al., 1995; Ishizuka and Lazar, 2003; Lazar, 2003). Deletion of individual components of the NCoR
complex results in an increase in liver triglycerides (Kulozik et al., 2011; Shimizu et al., 2015; Sun
et al., 2012), highlighting the importance of these proteins acting together as a functional complex
to regulate liver metabolic gene transcription.

The vast number of transcriptionally relevant complexes highlights the important roles proteinprotein interactions play in the control of gene expression. For HDAC3, there are important
questions about which transcription factors recruit it to the genome, and which HDAC3-associated
36

proteins act as downstream effectors to impact lipid gene regulation and hepatic steatosis. Here
we describe NEAT ChIP-MS (Nuclear Extraction Affinity Tag), an improved chromatin cross-linking
method followed by nano liquid chromatography-tandem mass spectrometry (nLC-MS/MS)
analysis to identify in vivo interactions in liver and define a high-confidence interactome for HDAC3.
We find a strong association between HDAC3 and the Prospero-related homeobox 1 protein
(PROX1), which co-localize at the genome and at some sites are completely dependent on the
nuclear receptor HNF4 for their co-recruitment. Interestingly, depletion of PROX1 in liver results
in increased hepatic triglycerides similar to loss of HDAC3. Our results suggest an important role
for an HDAC3-PROX1 corepression module in regulating the transcription of a gene program
important for the maintenance of lipid homeostasis.

3.3 METHODS
3.3a Animal studies
Male wild-type C57BL/6 mice were purchased from Jackson labs. Hdac3fl/fl mice generated inhouse were described previously (Sun et al., 2012). Hnf4fl/fl animals were a kind gift of Dr. Klaus
Kaestner (Parviz et al., 2002). Mice were housed in a temperature-controlled specific-pathogenfree facility under 12 hour light/dark cycles (lights on at 7:00, off at 19:00). Adult male mice between
the ages of 10-16 weeks old were used in all experiments unless otherwise indicated. AAV8 TBG
Cre was intravenously injected at 1.5×1011 GC per mouse to induce hepatocyte-specific gene
knockout, using AAV8 TBG GFP as a negative control. For MS experiments AAV8 TBG HDAC3HA or control AAV8 TBG HA-EGFP vectors were injected at 5×1010 GC per mouse in combination
with either AAV8 TBG Cre or AAV TBG GFP respectively. All mice in an experiment received equal
total dosages of AAV vectors by supplementing with AAV8 TBG empty or AAV8 TBG GFP vectors
where appropriate. All mice were euthanized by CO 2 inhalation followed by tissue harvest at 2
weeks after viral injection at ZT10 except indicated otherwise. All animal procedures followed the
guidelines of the Institutional Animal Care and Use Committee of the University of Pennsylvania.
37

3.3b Constructs and viral vectors
AAV8 TBG viral constructs for the expression of HA-EGFP and HDAC3-HA were generated by
PCR cloning and Gibson Assembly. All constructs were sequence verified by Sanger sequencing
at the Penn Genomic Analysis Core. Adeno-associated viruses were produced and purified by the
University of Pennsylvania Vector Core. AAV-based knockdown vectors were generated through
Gibson cloning of Egfp and the UltramiR mir-30 scaffold (Knott et al., 2014) into a modified AAV8
TBG vector containing a downstream Woodchuck Hepatitis Virus Posttranscriptional Regulatory
Element (WPRE). Two target sequences used for Prox1 knockdown, determined using the
shERWOOD algorithm (Knott et al., 2014), were: (TTCAGAGCAGGATGTTGAATA) and
(GAGAAGGCAGCAACAAAGAAA). The control shRNA sequence targeting Luciferase was
(CGCTGAGTACTTCGAAATGTC). For in vivo knockdown experiments mice received 1×1012 GC
per mouse of each Prox1 targeting virus or 2×1012 GC per mouse of the control shLuciferase virus.
For enhancer luciferase reporter vectors, enhancers for G0s2 were selected by comparing
H3K27Ac and GRO-seq tracks (GEO Accession number GSM1437738) (Fang et al., 2014) with

MCS of the pGL4 luciferase reporter system (Promega). pRL-SV40 renilla was used as a control
for firefly luciferase expression. Primers used in this study can be found in Table 3.2.

3.3c Liver triglyceride measurement and Oil Red O staining
For measuring triglyceride, livers were lysed in lysis buffer (140 mM NaCl, 50 mM Tris and 1%
Triton X-100, pH 8.0) followed by triglyceride assay using LiquiColor kit (Stanbio). Oil Red O
staining was performed by the University of Pennsylvania Center for Molecular Studies in Digestive
and Liver Disease Molecular Pathology & Imaging Core.

3.3d Cell culture and Luciferase Assay
HEK 293T cells purchased from ATCC were maintained in DMEM medium containing 10% FBS
and 100 ug/ml Penicillin/Streptomycin at 5% CO 2 and 37°C. Transfections of plasmids for the
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expression of proteins and luciferase reporter constructs were performed using Fugene 6 (Roche).
For luciferase assays, after 18-24 hours of transfection, cells were washed once with PBS followed
by lysis in passive lysis buffer (Promega). Lysates were analyzed for firefly and control renilla
luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer's instructions and read on a microplate reader equipped with a dual-injection system
(BioTek).

3.3e Immunoprecipitation and western blotting
For western blot analysis of total lysates, samples were lysed in a TissueLyser (Qiagen) in
radioimmunoprecipitation assay buffer (RIPA buffer) supplemented with Complete EDTA-free
protease inhibitor (Roche) and 1 mM PMSF. Samples were resolved by Tris-glycine SDS-PAGE
(Biorad), transferred to nitrocellulose membrane (Biorad), and blotted with the indicated antibodies.
Antibodies for western blotting were anti-PROX1 (Millipore, 07-537), anti-HDAC3 (GeneTex,
GTX113303), anti-HNF4 (Santa Cruz, sc-8987), anti-HA 3F10 High Affinity (Roche,
12013819001), anti-FLAG M2 (Sigma, A8592), anti-Actin (Santa Cruz, sc-1616) and anti-HSP90
(Cell Signaling, 4874). For immunoprecipitation followed by western blot livers were cross-linked
with 2 mM dithiobis(succinimidyl propionate), DSP (Pierce) in PBS at room temperature for 30 mins,
quenched with glycine, washed with ice cold PBS, and subsequently lysed in RIPA buffer
containing protease inhibitors and PMSF. Samples were pre-cleared with protein A sepharose CL4B (GE Healthcare), and incubated with either anti-HA agarose (Sigma, A2095) or with anti-HDAC3
(GeneTex, GTX113303) or anti-PROX1 (Millipore, 07-537) antibodies and captured with TrueBlot
anti-Rabbit IgG agarose (Rockland). Immunoprecipitates were washed 5 times with RIPA and
eluted with SDS loading dye. For in vitro coimmunoprecipitation analysis, HEK 293T cells were
transfected with pcDNA FLAG-NCOR1 or PROX1 vectors with Fugene 6 (Promega). For domain
mapping of PROX1 interaction with HDAC3, pcDNA FLAG-tagged PROX1 mutants, HDAC3-HA
and EGFP were transfected as indicated. At 72 hours after transfection, cells were washed with
PBS and lysed in IP buffer (50 mM Tris 7.4, 150 mM NaCl, and 0.5% NP-40) containing protease
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inhibitors and 1mM PMSF. Samples were pre-cleared with protein A sepharose CL-4B (GE
Healthcare), and incubated with anti-FLAG M2 resin (Sigma, A2220). Immunoprecipitates were
washed 5 times with IPLS and eluted with SDS loading dye for western blot analysis.

3.3f Mass spectrometry
Livers from Hdac3fl/fl animals transduced with AAV8 TBG HDAC3-HA and AAV8 TBG Cre or AAV8
TBG HA-EGFP and AAV8 TBG EGFP were harvested after 2 weeks of infection. A 250 mg sample
of liver was dissected, dounced 10 strokes with pestle A in 15 ml swelling buffer (10 mM Tris-HCl
pH 7.4, 2 mM MgCl2, 3 mM CaCl2) supplemented with 1 mM PMSF, and incubated for 20 mins on
ice. Swelled cells were dounced 15 strokes with pestle B, an additional 15 ml swelling buffer with
PMSF was added, filtered through a 100 µm cell strainer, and spun at 400 x g for 10 mins to collect
cells. Cells were resuspended in 5 ml swelling buffer with 10% glycerol and PMSF and an additional
5 ml of swelling buffer supplemented with 10% glycerol, 1% NP-40, and 1 mM PMSF was added
slowly while vortexing. Following lysis, nuclei were washed 1 time with PBS and subsequently fixed
with 1% formaldehyde diluted in PBS for 15 mins at room temperature. Cross-linked samples were
quenched with glycine, washed once with PBS, and resuspended in 1 ml NCB (20 mM Tris-HCl pH
8.0, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-40, 1 mM DTT) supplemented with
Complete EDTA-free protease inhibitor tablet (Roche) and 1 mM PMSF. Lysis was allowed to
proceed for 1 hour followed by sonication with a probe sonifier (Branson). Cross-linked chromatin
extracts were cleared by centrifugation and where indicated samples were treated with 1,000 Kunitz
units of either micrococcal nuclease (NEB) or Benzonase nuclease (Sigma) for 30 minutes at 30°C.
Extracts were immunoprecipitated with anti-HA agarose (Sigma, A2095) overnight, washed 3 times
in NCB supplemented with protease inhibitors and 1 mM PMSF, washed 2 times in NCB, washed
2 times in HPLC-grade water, eluted with 10% ammonium hydroxide diluted in HPLC-grade water,
and dried to completion in a SpeedVac (Eppendorf).
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Samples were prepared for MS as previously described (Armour et al., 2013). After
reduction/alkylation, samples were digested with LysC (Wako) for 2 hours followed by Trypsin
(Promega) at 37°C overnight. Samples were resuspended in 1% acetic acid, and desalted with C 18
stage tips, as previously described (Rappsilber et al., 2003). EASY-nanoLC (Thermo Fisher
Scientific) was configured with a 75 µm ID x 17 cm Reprosil-Pur C18-AQ (3 µm; Dr. Maisch GmbH,
Germany) nano-column and coupled with an Orbitrap Fusion mass spectrometer (Thermo Fisher
Scientific). Full scan MS spectrum (m/z 360−1600) was performed in the Orbitrap with a resolution
of 120,000 (at 200 m/z). Fragmentation was performed with higher-energy collisional dissociation
(HCD) and a maximum injection time of 120 msec. MS/MS data were collected in centroid mode in
the ion trap mass analyzer. Peptides were identified using MaxQuant (v1.5.3.30) using the Mus
Musculus UniProt FASTA database (March 2016) with an FDR<1% at the peptide spectrum match
and protein levels. Protein abundance was deconvoluted from peptide intensity using the intensitybased absolute quantification (iBAQ) (Schwanhäusser et al., 2011) algorithm, followed by log2
transformation, normalization by the median intensity, and missing values imputed (width 0.25,
downshift 2.0) using Perseus (v1.5.5.3). Significance was estimated using a two-tailed
homoscedastic t-test (p-value<0.05).

3.3g RT-qPCR and RNA-seq
Total RNA was extracted using TRIzol (Invitrogen) and RNeasy mini kit (Qiagen). Contaminating
DNA was removed using the RNase-Free DNase Set (Qiagen) on-column digestion protocol per
manufacturer's instructions. RT-qPCR was performed with the High Capacity RT kit (Thermo Fisher
Scientific), Power SYBR Green PCR Master Mix (Thermo Fisher Scientific), and a QuantStudio™
6 Flex Real-Time PCR System (Thermo Fisher Scientific) using absolute quantification method with
standard curves. 36b4 (Arbp) was used as housekeeping control. RNA-seq libraries were
generated using the Tru-seq kit (Illumina). Raw reads were aligned to the mm9 reference genome
using Tophat version 2.1.9 using the parameters recommended by the original author (Trapnell et
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al., 2012a). Differential expression analysis was performed using CuffDiff 2 (Trapnell et al., 2012b)
using default parameters.

3.3h ChIP-qPCR, ChIP-reChiP, and ChIP-seq
ChIP and ChIP-seq were as described previously (Feng et al., 2011; Lim et al., 2015). Briefly, livers
were mildly dissociated by dounce with pestle A for 6 strokes in PBS containing 1% formaldehyde
and rocked for 15 min, quenched with glycine, washed with PBS, and sonicated with a probe-type
sonifier (Branson) in RIPA supplemented with protease inhibitors and PMSF. Sonicated extracts
were immunoprecipitated with antibodies for HDAC3 (Abcam, ab7030), PROX1 (Millipore, 07-537),
HNF4 (Santa Cruz, sc-8987), or H3K27Ac (Abcam, ab4729), and captured with bovine serum
albumin blocked CL-4B protein-A sepharose beads (GE). PROX1 ChIP-seq was validated by
comparing results of ChIP-seq with two different PROX1 antibodies raised against separate
epitopes (Millipore, 07-537 and Proteintech 51043-1-AP), which showed a highly significant
Pearson correlation (R=0.96). The HNF4 and HDAC3 antibodies used for ChIP in this study have
been validated previously (Odom et al., 2004; Papazyan et al., 2016a).

ChIP-reChIP from 3 biological replicate livers was performed essentially as standard ChIP, except
following the first IP chromatin-protein complexes were eluted in 1% SDS with 10 mM DTT for 15
mins at 65°C. Subsequent to elution of the first ChIP, complexes were re-diluted in 10 volumes
RIPA supplemented with protease inhibitors (Roche), PMSF (Sigma), 5 mg/ml BSA, and 2 µg
Lambda DNA/HindIII (NEB), followed by a second ChIP with the either anti-rabbit IgG (Cell
Signaling Technologies, #2729) or the indicated antibody.

For ChIP-seq, ChIP was performed independently on livers from different mice (n=3). The
precipitated DNA samples were barcoded and amplified according Illumina guide protocols,
followed by deep sequencing on a HiSeq 2000 (Illumina). Sequencing reads of biological replicates
for PROX1 and HDAC3 were aligned to the mm9 genome using Bowtie v0.12.7 (Langmead et al.,
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2009b). Duplicate reads were removed and replicates were pooled using HOMER v4.7 (Heinz et
al., 2010). Genome browser tracks were generated and peaks were called using HOMER with
default parameters and IgG as input. Peaks more than 3-fold over input and >2 rpm in PROX1 and
>1.5 rpm in HDAC3 were used for further downstream analyses. Venn diagram was generated
using bedtools v2.26.0 (Quinlan and Hall, 2010b) and Vennerable R package with peaks
overlapping at least 50% and having at least 1 rpm in the other ChIP-seq. Motif analyses were
performed with HOMER using 200bp peak windows. Gene ontology was performed using
Reactome 2016 (Fabregat et al., 2016). Track visualization was performed using the Integrated
Genomics Viewer (Broad Institute) (Thorvaldsdottir et al., 2013).

Sequencing reads of biological replicates for PROX1, HDAC3, and HNF4 in Hnf4fl/fl and Hnf4
conditional liver knockout animals were processed similarly. Previously published C/EBP ChIPseq (GEO Accession numbers GSM1816821 and GSM1816822, replicates combined) (Bauer et
al., 2015) and C/EBPβ ChIP-seq (GEO Accession number GSM1446070) (Lim et al., 2015) were
re-processed using the same parameters. Peaks >1 rpm for PROX1 and HDAC3 and >2 rpm for
HNF4 were used for further downstream analyses. Scatter plots and box plots were generated
using the HOMER annotatePeaks command and R.

3.3i Data availability
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through GEO Series accession number GSE90533
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90533). All mass spectrometry data
reported here have been deposited in Chorus under ID number 1251.
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3.3j Statistical Methods
Data are presented as mean ± s.d. unless otherwise stated. Microsoft Excel software, GraphPad
Prism 7, MathWorks MATLAB, or R was utilized for all graphing and statistical tests. For
comparison between two groups, Two-tailed unpaired Student’s t-test were utilized unless
otherwise stated, where p<0.05 was considered statistically significant and the significance is
marked by *p<0.05, **p<0.01, and ***p<0.001 unless otherwise noted. Wilcoxon-Mann-Whitney
test was performed for statistical comparison between HNF4 binding and C/EBP or C/EBPβ
binding in the HDAC3-PROX1 down peaks in Hnf4 liver KO vs HDAC3-PROX1 unchanged peaks
in Hnf4 liver KO (Figure 3.11D) and exact p-values were reported. For correlation analysis of
HDAC3-PROX1 coregulated genes with HNF4-dependent binding sites, a Chi-squared
contingency table with Yates correction was used. All other statistical comparisons for two groups
of peaks were done using Pearson's Chi-squared contingency table tests and p-values were
reported for each pair. All statistical tests are fully described in figure legends. The required sample
size was calculated based on similar experiments and analyses carried out previously. The number
of animals in each experiment is stated in the respective figure legends.

3.4 RESULTS
3.4a In vivo screen for HDAC3 interactors
To elucidate nuclear interactors of HDAC3 in vivo, we developed NEAT ChIP-MS, a cross-linking
proteomic interaction method that allowed for the confident identification of HDAC3 interactors in
adult liver (Figure 3.1A). Hdac3fl/fl animals were tail vein-injected with either AAV virus expressing
epitope tagged HDAC3 (AAV8 TBG HDAC3-HA) in conjunction with AAV8 TBG Cre to deplete
endogenous HDAC3 in hepatocytes as described (Sun et al., 2012), or with control virus expressing
epitope tagged green fluorescent protein (AAV8 TBG HA-EGFP). Subsequent to nuclear isolation,
samples were cross-linked and EGFP or HDAC3 was immunoprecipitated with anti-HA resin.
Associated proteins were analyzed by nLC-MS/MS and the results of the HDAC3 and EGFP
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interactomes were compared to remove non-specific interactions. We applied stringent significance
(p<0.01) and fold enrichment (10-fold) cutoffs using label-free quantification values estimated by
the intensity-based absolute quantification (iBAQ) (Schwanhäusser et al., 2011) algorithm to the
resultant interactome to identify a set of high-confidence HDAC3 interacting proteins in vivo in
mouse liver (Figure 3.2A and Table 3.1).

As expected, we observed an enrichment of all the components of the previously identified NCoR
complex (sequence coverage indicated in parentheses) consisting of NCOR1/2 (11.14%/12.14%),
TBL1X (46.62%), TBL1XR1 (42.52%), GPS2 (4.33%), and HDAC3 (42.85%) itself. In addition, our
screen confirmed interaction of HDAC3 with a number of transcription factors known to interact with
the NCoR complex, including the circadian nuclear receptor Rev-erb (Feng et al., 2011; Hu et al.,
2001). One of the most significantly enriched HDAC3 interactors, but not considered a core
component of the NCoR complex, was the Prospero-related homeobox 1 (PROX1). A highly
conserved transcription factor in vertebrates, PROX1 was previously shown to be critical for the
development of several organs including the lymphatic system (Wigle and Oliver, 1999), lens (Wigle
et al., 1999), liver (Burke and Oliver, 2002; Seth et al., 2014; Sosa-Pineda et al., 2000), pancreas
(Burke and Oliver, 2002; Wang et al., 2005), heart (Risebro et al., 2009), and skeletal muscle
(Kivelä et al., 2016; Roy et al., 2001). Additionally, PROX1 has been implicated in regulating the
functions of several nuclear receptors (Charest-Marcotte et al., 2010; Dufour et al., 2011; Qin et
al., 2004; Song et al., 2006; Steffensen et al., 2004; Takeda and Jetten, 2013) and has been shown
to act as both a transcriptional repressor (Qin et al., 2004; Song et al., 2006; Steffensen et al.,
2004) and activator (Lengler et al., 2001; Wigle et al., 1999) in different biological contexts.

To assess whether the proteins discovered in our chromatin bound complexes purified with HDAC3
directly through protein-protein interactions or indirectly through close genomic proximity we treated
our lysates with either micrococcal nuclease (MNase), capable of cutting only in nucleosome free
regions, or Benzonase nuclease, which can cleave DNA regardless of nucleosome occupancy.
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Although micrococcal nuclease had minimal impact, Benzonase nuclease significantly reduced the
intensity of a subset of protein-protein interactions with HDAC3 (Figure 3.2B). This suggested that
these proteins are not in direct contact with HDAC3, and thus these protein-protein associations
are likely facilitated by DNA. Additionally, interactors associated with HDAC3 exhibiting lower
enrichments tended to be more susceptible to Benzonase treatment, implying that proteins
displaying greater abundance were, in general, more likely to occur through protein-protein
interactions. The group of proteins maintained upon nuclease treatment included PROX1,
indicating that this robust HDAC3 interactor was likely more directly bound and not dependent on
DNA bridging for its interaction.

The interaction of PROX1 and HDAC3 in liver was confirmed by co-immunoprecipitation
experiments using the reversible cross-linker DSP from livers expressing HA-tagged HDAC3 or
endogenously from wild-type livers (Figure 3.2C). PROX1 and HDAC3 interaction likely occurs in
the context of the NCoR complex, as interaction between PROX1 and NCOR1 was observed in
cell culture, and also requires multiple surfaces in the N-terminus of PROX1 for binding (Figure
3.3A and B). We next sought to better understand the HDAC3 interactome from a more global
functional perspective. Classifying the interactors and their biological links and annotating them
using information from the STRING database revealed several interesting clusters of proteins
associating with HDAC3 (Figure 3.4A). In addition to the NCoR complex, HDAC3 was found to
associate with several other transcriptionally important complexes including SWI/SNF, Integrator,
Cohesin, and components of the NuRD and CoREST repressor complexes. We also observed a
number of sequence-specific DNA binding transcription factors of functional relevance to liver
physiology such as C/EBPs, FXR, RXR and HNF4. We also utilized cytoHUBBA, a tool to define
network topology (Chin et al., 2014), and identified members of the NCoR complex, NuRD/CoREST
complex, Integrator complex, and nuclear receptors as important nodes in the liver HDAC3
interactome (Figure 3.5A). These results indicate that HDAC3 likely plays an important role in
regulating the expression of liver gene programs through interaction with an array of transcription
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factors and suggest that PROX1, as a strong interactor in liver, may be of more general importance
to the functionality of HDAC3.

3.4b PROX1 and HDAC3 co-localize extensively at the genome
To further investigate the functional interplay between PROX1 and HDAC3 we performed ChIPseq on PROX1 and HDAC3 in mouse liver. Bioinformatic analysis of the peaks discovered in the
two datasets revealed a strong overlap between the binding sites of the HDAC3 and PROX1
cistromes (Figure 3.6A). Visual inspection of individual ChIP-seq tracks confirmed a striking
correlation (Figure 3.6B). We next performed ChIP-reChIP analysis, which demonstrated that both
HDAC3 and PROX1 were co-bound to the same DNA fragments (Figure 3.6C). Analysis of
overlapping peaks by pathway analysis (Reactome) revealed that co-bound sites were enriched at
genes involved in a variety of important metabolic pathways, including those that regulate lipid
metabolism (Figure 3.6D). As expected peaks bound by HDAC3 selectively showed enrichment
both for liver metabolic genes and those involved in circadian rhythm, indicating that HDAC3 likely
has functions with Rev-erb independent of its interaction with PROX1 (Figure 3.7A). HOMER
motif analysis of the overlapping peaks displayed a strong enrichment for the HNF4 and C/EBP
motifs, two transcription factors that are known to play important roles in liver development and
adult liver function (Figure 3.8A). Upon closer examination of overlapping, HDAC3-only, and
PROX1-only peaks we observed that the HNF4 motif was significantly reduced at HDAC3-only
peaks, whereas the Rev-erb (DR2) motif was significantly enriched at these sites (Figure 3.8B).
The C/EBP motif followed a similar pattern observed for HNF4 indicating that it may also play a
role in coordinating these sites but not those involved in circadian function. These results suggest
that HDAC3 is recruited to at least two subsets of sites, ones that contain only HDAC3, which are
recruited by Rev-erb, and those that have both PROX1 and HDAC3, and are recruited by HNF4.
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3.4c HNF4 is required for the recruitment of the HDAC3-PROX1 module
Given our observation that the HNF4 motif was found prominently at co-occupied sites, we
hypothesized that this important liver transcription factor may play a role in the recruitment of
HDAC3 and PROX1. ChIP-seq analysis of HNF4 in control liver demonstrated HNF4 binding at
>60% of HDAC3-PROX1 co-bound peaks (Figure 3.9A). In stark contrast, HDAC3-only peaks
displayed significantly reduced HNF4 binding (~14%). Motif analysis of the triply bound peaks
showed an increased enrichment of the HNF4 motif and a mild de-enrichment of the C/EBP motif
when compared to all HDAC3-PROX1 co-bound peaks (Figure 3.9B). Co-binding of both PROX1
and HDAC3 with HNF4 nearby several lipid-related genes were confirmed by ChIP-reChIP
(Figure 3.9C and D). To address whether HNF4 was required for the recruitment of HDAC3PROX1 at the co-bound sites we injected Hnf4fl/fl mice with AAV8 TBG Cre to delete Hnf4 in
hepatocytes (Figure 3.10A). ChIP-seq analysis of HNF4 in these mice revealed near complete
loss of HNF4 binding at the genome (Figure 3.10B-D). Remarkably, a significant portion of both
HDAC3 and PROX1 peaks were strongly reduced upon loss of HNF4 (Figure 3.11A). Moreover,
the HDAC3 and PROX1 sites that were affected were almost exclusively the same sites (Figure
3.11B).

In addition, we observed a decreased interaction of PROX1 and HDAC3 in the Hnf4 knockout
mice by Co-IP western blot, suggesting HNF4 may be required to stabilize the HDAC3-PROX1
interaction in vivo (Figure 3.11C). We compared the binding of both HNF4 and C/EBPβ at the cobound sites that were lost in Hnf4 knockout versus those that were unaffected and observed a
positive relationship between the strength of HNF4 binding and the dependency of
HDAC3/PROX1 on HNF4 (Figure 3.11D). C/EBP, serving as a control comparison, did not display
a similar correlation. These results strongly suggest that HNF4 recruits the HDAC3-PROX1
module to a substantial subset of binding sites, while other factors, like C/EBP, may be more
important elsewhere in the genome.
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3.4d Liver depletion of PROX1 causes increased hepatic triglycerides
To determine the function of PROX1 in liver, Prox1 was knocked down in adult hepatocytes of wildtype male mice using an AAV-based shRNA delivery vector (AAV8 TBG shProx1), which led to a
~70% depletion in PROX1 protein 3 weeks following injection (Figure 3.12A). Hepatic triglycerides
(TG) were significantly elevated following 3 weeks of PROX1 knockdown, with a more striking
difference in TG levels observed at 6 weeks post infection (Figure 3.12B). Oil Red O staining
confirmed an increase in neutral lipid in livers of male mice infected with Prox1 shRNAs (Figure
3.12C). Importantly, no significant change in HDAC3 protein levels were observed upon knockdown
of PROX1 (Figure 3.12D). Thus, similar to HDAC3 knockout, depletion of PROX1 in liver results
in increased triglyceride content. Of note, hepatic PROX1 levels were not significantly changed
after 12 weeks of high fat diet (Figure 3.12E).

3.4e HDAC3 and PROX1 coregulate a lipid gene expression program
To determine if transcriptional mechanisms of coregulation by HDAC3 and PROX1 played a role
in regulating this striking liver lipid phenotype, we performed RNA-seq on Hdac3 knockouts and 3
week Prox1 shRNA livers. We observed a significant overlap of genes whose expression was
altered by loss of either factor, with a striking over-representation of genes whose directionality of
change was correlated and a strong preference for upregulated genes, consistent with the function
of both HDAC3 and PROX1 as transcriptional repressors (Figure 3.13A). Pathway analysis
(Reactome) revealed the group of transcripts co-upregulated by HDAC3 and PROX1 loss to be
highly enriched for regulation of lipid metabolism, including a number of important mediators of lipid
synthesis and lipolysis. Transcriptional coregulation of a number of genes whose expression are
critical to maintenance of lipid homeostasis, such as G0s2 (Wang et al., 2013), Elovl6 (Matsuzaka
et al., 2012), Mfsd2a (Berger et al., 2012) and Cidec (Matsusue et al., 2008) were confirmed by
qPCR following Hdac3 knockout or Prox1 knockdown (Figure 3.13B). Correlation analysis
comparing the frequency of HNF4-dependent HDAC3-PROX1 binding sites at unchanged and
HDAC3-PROX1 coregulated genes revealed a statistically significant relationship (Chi-square with
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Yates correction, p<0.0001). This association was consistent at lipid-related genes (Figure 3.14A),
and point to a strong correlation between co-upregulated lipid-related gene expression and the cooccupancy of HNF4-dependent, HDAC3-PROX1 co-bound sites.

Upon examination, a number of these loci exhibited a strong overlap of HDAC3, PROX1, and
HNF4 ChIP-seq signals, consistent with our genome-wide analysis (Figure 3.15A and Figure
3.16A). In addition, we observed upstream co-bound regions that exhibited high H3K27 acetylation,
suggesting that these sites may be putative enhancers. Indeed, upon loss of HDAC3 or PROX1
we observed an increase in HNF4-dependent H3K27 acetylation at these putative enhancer
regions. Moreover, analysis of nascent transcription, utilizing an existing global run-on sequencing
(GRO-seq) dataset in liver (Fang et al., 2014), revealed bi-directional enhancer RNAs (eRNAs) at
a number of co-bound regions. To determine if these binding sites act as enhancers we cloned the
G0s2 -17kb and -1.7kb binding sites into the pGL4 Luciferase reporter. Co-transfection of the
enhancer reporter plasmid with an HNF4 expression vector revealed strong transcriptional
induction by HNF4 at both the -17kb and -1.7kb sites. Interestingly, expression of PROX1
significantly repressed HNF4 mediated transcriptional activation, while it was unable to repress
trans-activation induced by C/EBP expression (Figure 3.16B). While mutation of the HNF4
binding site severely disrupted activation by HNF4 (Figure 3.17A and B). These data indicate
that the -17kb, and to a lesser extent the -1.7kb, binding sites act as HNF4-controlled enhancers
for the expression of G0s2 and that HDAC3 and PROX1 act as direct repressors of these
enhancers. Overall our results indicate that the interaction between HDAC3 and PROX1 is critical
for regulating liver metabolic gene expression and maintenance of hepatic lipid homeostasis
(Figure 3.18).
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3.5 DISCUSSION
In this study we determined in vivo protein interactors of the class I histone deacetylase HDAC3 in
mouse liver. This interactome revealed a number of novel binding partners in addition to confirming
the well-established role of HDAC3 as a component of the NCoR complex (Guenther et al., 2001;
Lazar, 2003; You et al., 2013). Amongst these binding partners we explored the functional
interaction between HDAC3 and the Prospero-related homeobox protein PROX1. We determined
that HDAC3 and PROX1 co-occupy a high number of genomic binding sites and that these binding
sites correlate strongly with both the DNA-binding motif and the cistrome of HNF4. Moreover,
upon loss of HNF4, a significant portion of HDAC3 and PROX1 co-occupied sites exhibit a
profound loss of genomic binding. Depletion of PROX1 specifically in mature adult liver resulted in
a dramatic increase in liver triglyceride content similar to that observed upon loss of HDAC3 (Sun
et al., 2012), likely due to the dysregulation of a coregulated gene expression program important
for lipid synthesis and lipolysis. Furthermore, we defined a novel liver enhancer responsible for
controlling the expression of the lipolysis inhibitor G0S2, and showed that its transcriptional
activation by HNF4 can be specifically repressed by PROX1. Overall, these results strongly
suggest HDAC3 and PROX1 function in liver to corepress gene transcription important for
maintenance of lipid homeostasis.

Protein-protein interactions are critical for determining biological functionality, including the control
of chromatin function and gene expression, and can be strongly influenced when a binding partner
is restricted to a specific cell type or tissue. Previous studies defining interacting partners for
HDAC3 by mass spectrometry have not provided significant depth or elucidated tissue-specific
factors bound with HDAC3 in vivo (Bantscheff et al., 2011; Guenther et al., 2000; Joshi et al., 2013;
Wen et al., 2000). Our strategy for identifying HDAC3 interactors in liver differs from methods that
have been successful in cultured cells (Mohammed et al., 2013) in two important ways. First,
through co-expression of fusion-tagged HDAC3 and Cre recombinase in Hdac3fl/f animals via
adeno-associated viral vectors (AAV8) under the control of the thyroxine binding globulin promoter
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(TBG), we were able to express our bait protein in vivo in hepatocytes lacking endogenous HDAC3.
Second, we found that cross-linking isolated nuclei rather than whole liver depleted significant
cytoplasmic and mitochondrial liver contaminants leading to reduced sample complexity and
increased depth and sensitivity of our interacting protein mass spectrometric identifications.
Nuclear isolation prior to functional assays, co-IP, and ChIP has been widely utilized in the
transcriptional field (Chaya and Zaret, 2003), most recently being employed for techniques such as
GRO-seq (Core et al., 2008) and INTACT (Mo et al., 2015). In addition, we have compared the
cistromes of HDAC3 from standard ChIP-seq and those produced with our protocol and found them
to be highly correlated (Pearson correlation, R=0.781), suggesting that the nuclear isolation step is
not having a major effect on the biological landscape that we are attempting to elucidate.

Similar to cross-linking methods developed for cultured cells (Mohammed et al., 2013), the present
method is improved in its ability to capture more transient interactions, including those at the
genome. Of note, although previous work has shown the circadian nuclear receptor Rev-erb and
other nuclear receptors to be interacting partners for the HDAC3-containing NCoR complex (Feng
et al., 2011; Ishizuka and Lazar, 2003), these proteins were not found in a previous HDAC3
proteomic screen performed in CEM T cells(Joshi et al., 2013). By contrast, the current study
revealed several important HDAC3-bound nuclear receptors in liver including HNF4, RXR, Reverb, and FXR, implicating HDAC3 in their functions. Our screen also revealed several non-nuclear
receptor sequence-specific transcription factors such as C/EBP, ChREBP, CREB1, and ETV6,
possibly pointing to a broader role of HDAC3/NCoR in corepressing non-nuclear receptor
transcription factors in liver. Alternatively, it is conceivable that our cross-linking based sample
preparation is capable of capturing targets of HDAC3 enzymatic activity. Indeed, a number of the
interactors elucidated in our screen have been shown to be regulated by lysine acetylation including
C/EBP (Bararia et al., 2016), ChREBP (Bricambert et al., 2010), CREB1 (Lu et al., 2003), and
others, and it is therefore interesting to speculate that HDAC3 may regulate their functions through
this mechanism.
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Interaction of HDAC3 was also observed with several important nuclear complexes such as
Integrator (Gardini et al., 2014; Lai et al., 2015), Cohesin (Kulemzina et al., 2016), SWI/SNF
(Euskirchen et al., 2011; Shi et al., 2013), and NuRD (Whyte et al., 2012), which have been
implicated in the regulation of transcription through binding and functional control of gene-specific
enhancers. Previous studies suggested that HDAC3 genomic binding correlates primarily with
regions of active transcription (Wang et al., 2009), which our results strongly support and extend to
suggest that these components of the transcriptional machinery may be involved.

It will be

interesting to determine if HDAC3 plays a role as a bona fide member of these complexes or rather
regulates their function through enzymatic or non-enzymatic mechanisms. The processes by which
transcriptional activators and repressors act together at these enhancers to specifically tune gene
expression remains an important unanswered question.

Although PROX1 has been shown to be critical for the development and specification of several
tissues (Burke and Oliver, 2002; Dyer et al., 2003; Risebro et al., 2009; Seth et al., 2014; SosaPineda et al., 2000; Wigle and Oliver, 1999; Wigle et al., 1999), its functions in the physiology of
adult liver have not been determined. Our study provides evidence that PROX1 in adult liver helps
maintain proper lipid homeostasis, as its depletion results in metabolic gene transcriptional changes
and a strong upregulation of hepatic triglycerides. A previous study suggested that
haploinsufficiency of Prox1 in mice results in obesity (Harvey et al., 2005), and these animals
exhibited an increase in liver lipids which was suggested to be secondary to obesity. Our results
suggest that the haploinsuffficiency of Prox1 in hepatocytes might also contribute to the
hepatosteatotic phenotype.

Unlike PROX1, which displays significant tissue specificity (Steffensen et al., 2004), HDAC3
expression is relatively ubiquitous. Even so, PROX1 and HDAC3 are implicated in the control of
several overlapping tissues such as pancreas, heart, central nervous system, and liver. Thus it is
possible that, in these biological contexts, PROX1 provides tissue-specific functionality to HDAC3
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through protein-protein interaction. HDAC3 has been implicated in beta cell function and the
regulation of glucose homeostasis (Remsberg et al., 2017). Interestingly, genome-wide association
studies have revealed a CC variant SNP of Prox1 (rs340841) that contributes to the control of
fasting glucose levels and the development of diabetes (Dupuis et al., 2010; Lecompte et al., 2013).
Perhaps in pancreatic beta cells, as in liver, HDAC3 and PROX1 form a complex to regulate gene
expression involved in the control of organismal metabolism.

Non-alcoholic fatty liver disease (NAFLD) is a disorder whose prevalence is increasing alongside
metabolic syndrome, obesity, and type 2 diabetes and affects as high as 30% of the adult
population in developed countries (Browning and Horton, 2004; Tilg et al., 2016). As a major risk
factor for liver inflammation (NASH) and scarring/fibrosis (Cohen et al., 2011), understanding the
molecular mechanisms of liver function is of critical importance to development of therapies for this
unmet medical need. Here we have defined an interaction between HDAC3 and PROX1 that is
nucleated at the genome by HNF4, and elucidated the role of this repressor module in controlling
hepatic triglyceride content by modulating lipid synthesis and lipolytic gene expression. These
results highlight the importance tissue-specific corepressor interactions in maintaining liver
metabolism and illustrate new pathways for therapeutic intervention.
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A

Figure 3.1 NEAT ChIP-MS workflow to interrogate the HDAC3 liver nuclear interactome. (A)
Schematic illustration of the NEAT ChIP-MS protocol. HA-tagged HDAC3 or EGFP was expressed
with or without Cre in Hdac3fl/fl mice specifically in hepatocytes via adeno-associated virus (AAV8
TBG). After isolation of nuclei and cross-linking with formaldehyde, HDAC3 or EGFP control were
captured by anti-HA immunoprecipitation. Protein complexes and associated DNA sequences were
analyzed by mass spectrometry or high-throughput sequencing respectively.
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Figure 3.2 HDAC3 liver interactome by NEAT ChIP-MS reveals PROX1 as an abundant
interactor. (A) Volcano plot of mass spectrometry analysis of HDAC3 interacting proteins (HDAC3
n=11, EGFP n=13). The x-axis indicates log2 ratio of normalized intensity (iBAQ) of proteins
discovered in HDAC3 to EGFP control. Red box indicates fold-change (10-fold) and p-value (0.01)
cutoffs for interactors. Core NCoR complex components (blue), selected high scoring interactors
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(red), and Rev-erb (green) are indicated. (B) Heatmap of normalized intensity (iBAQ) of HDAC3
interactors from A in the presence or absence of micrococcal nuclease (MNase) or Benzonase
nuclease. Each lane represents an independent experiment. (C) Co-IP experiments confirming
interaction of HDAC3 with PROX1 from liver expressing tagged HDAC3 (top) or endogenous IPs
(bottom).
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Figure 3.3 Interrogation of PROX1 interaction with HDAC3-NCoR. (A) Co-immunoprecipitation
western blot analysis of FLAG-NCOR1 co-expressed with PROX1 in HEK 293T cells. (B) Domain
mapping to identify regions of PROX1 required for interaction with HDAC3. FLAG-tagged PROX1
truncations were co-expressed with HDAC3-HA in HEK 293T cells and subjected to FLAG
immunoprecipitation followed by western blotting.
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Figure 3.4 HDAC3 interactome network. (A) Protein-protein interaction network analysis. Circle
color represents enrichment over control and the size of the circle represents -log10(p-value). Nodes
displayed met 8-fold enrichment cutoff after Benzonase treatment and lines indicate validated
interactions (STRING, active interaction sources include experiments and databases, minimum
interaction score 0.6). Interactors are grouped by known type and circles indicate known functional
complexes.
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Figure 3.5 HDAC3 interactome topology analysis. (A) cytoHUBBA analysis using the maximal
clique centrality (MCC) of HDAC3 interactors annotated from STRING. Active interaction sources
include experiments and databases with a minimum interaction score of 0.6. Nodes are colored by
rank order.
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Figure 3.6 HDAC3 and PROX1 exhibit extensive co-binding and reveal a metabolic signature.
(A) Venn diagram displaying overlap of peaks identified in PROX1 (2 rpm cutoff) and HDAC3 (1.5
rpm cutoff) ChIP-seq. Peaks required 50% overlap and have a minimum 1 rpm signal for the other
factor. (B) Representative browser tracks of HDAC3 and PROX1 ChIP-seq. Scale is reads per ten
million (RPTM). (C) Co-occupancy of PROX1 and HDAC3 as indicated by ChIP-reChIP (n=3) from
liver. Legend indicates reChIP antibody following primary PROX1 ChIP elution. Data are presented
as mean±s.d., one-tailed unpaired Student’s t-test, *p<0.05, **p<0.01, ***p<0.001, ns not
significant. (D) Reactome analysis of the nearest genes within 100kb from the top 1000 overlapping
HDAC3 and PROX1 peaks.
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Figure 3.7 HDAC3 and PROX1 specific cistromic analysis. (A) Reactome analysis of the
nearest genes within 100kb from the top 1000 HDAC3-specific and PROX1-specific peaks.
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Figure 3.8 Interrogation of cistrome data suggests distinct HDAC3 containing chromatin
complexes. (A) HOMER motif analysis of co-bound peaks displaying over-represented
sequences. (B) HOMER motif enrichment analysis of the indicated motifs (HNF4, CEBP bZIP,
and Rev-erb DR2) at overlapping and non-overlapping peaks determined in Figure 3.6A.
Numbers above brackets indicate p-values, Chi-squared test.
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Figure 3.9 The HDAC3-PROX1 module is recruited by HNF4 in liver. (A) Comparison of
HNF4 binding (> 2 rpm, filtered on the HNF4 KO, 50% minimum overlap) at overlapping and
non-overlapping peaks in the HDAC3 and PROX1 cistromes from Figure 3.6A. Numbers above
brackets indicate p-values, Chi-squared test. (B) HOMER motif analysis of peaks co-bound by
HDAC3, PROX1, and HNF4 displaying over-represented sequences. (C, D) Co-occupancy of
HDAC3-PROX1 and HNF4 as indicated by ChIP-reChIP (n=3) from liver. Legend indicates reChIP
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antibody following primary HDAC3 or PROX1 ChIP elution. Data are presented as mean±s.d, onetailed unpaired Student’s t-test, *p<0.05, **p<0.01, ***p<0.001, ns not significant.
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Figure 3.10 HDAC3, PROX1, and HNF4 genomic binding in control and Hnf4 knockout
liver. (A) Western blot confirming HNF4 knockout. (B-E) Representative browser tracks at lipidrelated genes of HNF4, PROX1, and HDAC3 ChIP-seq in Hnf4fl/fl livers infected with AAV8 TBG
Egfp (Ctl) or Cre (Hnf4 KO). Indicated scales are in RPTM.
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Figure 3.11 The HDAC3-PROX1 module requires HNF4 for a majority of binding sites in
liver. (A) Scatter plots of PROX1 (left) and HDAC3 (right) ChIP-seq in control versus Hnf4 KO.
Red and blue shaded regions indicate a 2-fold decrease in peak intensity upon loss of HNF4. (B)
Venn diagram displaying overlap (at least 50% and 1 rpm) of red and blue regions from A. (C) Coimmunoprecipitation western blot of HDAC3-HA in control and HNF4 KO liver. (D) Box and
whisker plot indicating the ChIP-seq binding strength of HNF4, C/EBP, and C/EBP at HDAC3PROX1 sites that are either down upon loss of HNF4 (purple) or unchanged (gray) (WilcoxonMann-Whitney test).
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Figure 3.12 PROX1 knockdown causes an increase in hepatic triglyceride content. (A)
Western blot of liver samples from mice treated for 3 weeks with AAV8 TBG shLuciferase (Prox1
Ctl) or shPROX1 (Prox1 KD). Densitometry of the western blot shown above (n=3). Data are
presented as mean±s.d. (B) Hepatic triglyceride assay of livers infected for 3 weeks (n=3) or 6
weeks (n=6) with indicated virus. Data are presented as mean±s.d. (C) Oil red O staining of livers
infected for 6 weeks as in B. Scale bar is 50µm. (D) Western blot of HDAC3 in control and PROX1
KD liver. (E) Western blot showing PROX1 levels in male mice at 18 weeks of age fed for 12 weeks
with normal chow diet (NC) or high fat diet (HFD).
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Figure 3.13 Transcriptomic analysis reveals the HDAC3-PROX1 module suppresses
steatosis by controlling a hepatic lipid metabolism gene program. (A) RNA-seq analysis of
Hdac3fl/fl mice infected for 2 weeks with AAV8 TBG Egfp (n=2) or Cre (Hdac3 KO, n=3) vs. wildtype mice infected with AAV8 TBG shLuciferase (n=3) or shPROX1 (Prox1 KD, n=3) for 3 weeks.
Heatmap displays coregulated genes (1.7-fold change, p<0.05) grouped by expression correlation
(135 genes) or anti-correlation (50 genes) upon ablation of HDAC3 or PROX1. Inset shows the pvalue and corresponding gene list for the highest ranking Reactome pathway in the co-upregulated
cluster. (B) Confirmation of up-regulated lipid-related genes upon loss of HDAC3 (Ctl n=4, KO n=6)
or PROX1 (Ctl n=3, KD n=3) by qPCR. Data are presented as mean±s.d. Two-tailed unpaired
Student's t-test, *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.14 RNA-seq and ChIP-seq correlation analysis of HDAC3-PROX1 module recruited
by HNF4. (A) Heatmap displays co-upregulated lipid-related genes upon ablation of HDAC3 or
PROX1 and the corresponding binding strength of adjacent HDAC3-PROX1 co-bound peaks (50kb upstream of the transcription start site, TSS through +2kb from the transcription end site,
TES) in the HNF4 KO liver relative to control. Scale bar represents log2(fold change) for RNA-seq
and fold-change for ChIP-seq.
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Figure 3.15 Genomic binding and nascent transcription near lipid-related genes coregulated
by HDAC3-PROX1. (A) Example ChIP-seq and GRO-seq browser tracks at lipid-related gene loci.
Indicated scales are in RPTM.
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Figure 3.16 HDAC3-PROX1 repress putative G0s2 enhancers. (A) Example ChIP-seq and
GRO-seq browser tracks at the G0s2 locus. Red boxes indicate location of putative G0s2
enhancers. (A) Luciferase assay (n=3) indicating transcriptional response to co-expression of
HNF4, PROX1 and C/EBP at G0s2 enhancers as identified in A. Data are presented as
mean±s.d. Two-tailed unpaired Student's t-test, *p<0.05, **p<0.01, ***p<0.001, ns not significant.
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Figure 3.17 HNF4-induced enhancer function is dependent on an intact HNF4 DNA
binding motif. (A) Track of G0s2 locus with identified HNF4 motif. Indicated scales are in RPTM.
(B) Luciferase assay (n=3) indicating transcriptional response to expression of HNF4 at wild-type
and HNF4 DR1 mutant G0s2 enhancer as indicated. Data are presented as mean±s.d, two-tailed
unpaired Student's t-test, *p<0.05, **p<0.01, ***p<0.001, ns not significant.
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Figure 3.18 Schematic model of HNF4 recruitment of PROX1 and the NCoR complex to
regulate a lipid-related metabolic gene program.
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Table 3.1 nLC-MS/MS analysis of HDAC3 high-confidence interacting proteins. Proteins
listed met 10-fold enrichment versus EGFP and p<0.01.
Protein
names

log2(HDAC3/EGFP)

negative
log10(p-value)

Classification

Hdac3

11.50137525

5.021516227

NCoR Complex

Tbl1x

10.54659342

7.587663608

NCoR Complex

9.24165353

8.95026059

NCoR Complex

Ncor1

8.825403468

6.17251732

NCoR Complex

Ncor2

7.603407958

10.08949853

NCoR Complex

Prox1

7.595525418

7.097347584

Transcription/Chromatin

Mlf2

7.574741457

4.436019601

Gps2

7.571426065

5.232233167

NCoR Complex

Rxra

7.341950491

3.327213956

Nuclear Receptor

Nfix

7.148035567

6.644835182

Transcription Factor

Rcor1

6.345118027

2.712611201

NuRD/CoREST

Cebpa

6.183333282

5.339815886

Transcription Factor

Nr1h4

6.072994963

4.176496378

Nuclear Receptor

Bag5

6.070137242

4.234131552

Dnajb4

6.061957981

3.589209458

Etv6

6.048757593

2.938893161

Transcription Factor

Smarcd2

6.037286742

4.958741634

SWI/SNF

Znf281

6.032345368

3.792904085

Transcription Factor

Zhx2

5.794752614

3.679940103

Transcription/Chromatin

Mlxipl

5.773455481

3.568588182

Transcription Factor

5.53567459

4.508312652

NuRD/CoREST

Clock

5.366657793

4.746470225

Transcription Factor

Wrnip1

5.319348837

2.782480267

Transcription/Chromatin

Dpf2

5.306182493

3.913796445

Transcription/Chromatin

Nosip

5.285065555

3.559607131

Nr1d1

5.234286657

2.47193724

Pias1

5.167487939

2.166612423

Transcription/Chromatin

Vwa9

5.116103328

3.191066711

Integrator

Asun

5.092654541

2.81531689

Hnf1a

5.078858612

5.410401383

Transcription Factor

Mta1

5.078814908

2.541132063

NuRD/CoREST

Ppara

5.058586349

2.476820827

Nuclear Receptor

Smarcc2

4.978585848

6.199303917

SWI/SNF

Smarcb1

4.964746211

2.228178493

SWI/SNF

Nfib

4.908651202

4.305886841

Transcription Factor

Tbl1xr1

Kdm1a
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Nuclear Receptor

Stat5b

4.892492597

2.889276943

Transcription Factor

Mau2

4.874084295

2.567924363

Cohesin

Arntl

4.865380227

2.406360822

Transcription Factor

Brd4

4.858912757

3.375470207

Transcription/Chromatin

Zhx3

4.847763471

3.957113425

Transcription/Chromatin

4.82836982

2.321889843

Ints5

4.778638786

3.342287612

Integrator

Smarce1

4.604676132

2.485552012

SWI/SNF

Gatad2b

4.555632328

4.500371592

Transcription/Chromatin

Zbtb7b

4.547599544

2.682269053

Transcription/Chromatin

Dbp

4.547080983

2.735498485

Transcription Factor

Hnf4a

4.525649856

6.605898044

Nuclear Receptor

Cebpb

4.520503791

2.100955859

Transcription Factor

Smc1a

4.517900637

4.010252604

Cohesin

Arid5b

4.498504251

2.497245671

Transcription/Chromatin

Ruvbl2

4.496709142

4.099500642

Transcription/Chromatin

Ints1

4.477111894

4.212996556

Integrator

Smarca5

4.475990697

4.381754785

SWI/SNF

Arid1a

4.46676445

4.512961942

SWI/SNF

Nab1

4.462064744

5.296508944

Transcription/Chromatin

Ints9

4.370964709

3.150054586

Integrator

Polr2b

4.289036511

4.049194873

Transcription/Chromatin

Bhlhe40

4.256751257

2.152211759

Transcription Factor

Smc3

4.228886734

3.439928347

Cohesin

Mnat1

4.18744312

3.441859023

Transcription/Chromatin

Ints6

4.09958548

2.771826393

Integrator

Ints4

4.099168822

4.407380393

Integrator

Nfic

4.082154089

5.771828847

Transcription Factor

Zhx1

4.066760579

2.562358274

Transcription/Chromatin

Nr3c1

4.046922931

2.645929979

Nuclear Receptor

Ints3

4.04490837

4.1286784

Stag2

4.020063973

4.266083132

Cohesin

Esrra

4.00522078

2.123791729

Nuclear Receptor

Paf1

3.995728504

3.041862816

Transcription/Chromatin

Hspa1b;Hspa1a

3.970119408

3.388227113

Nfia

3.965017835

4.687516874

Esrp2

3.914764469

2.908276725

Gstm6

3.866886589

2.572367699

Rbbp7

3.86528679

3.890890089

NuRD/CoREST

3.855895003

4.104064485
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Transcription/Chromatin

Sult1a1

Ctr9

Integrator

Transcription Factor

Chd4

3.831952941

5.822887135

NuRD/CoREST

Creb1;Atf1

3.829080483

2.774269322

Transcription Factor

Usf2

3.798018588

2.156114993

Transcription Factor

Smarca2

3.781494617

5.13107819

Dnajb1

3.774240199

2.140052457

Smarca4

3.717048017

2.776681779

SWI/SNF

Gtf2i

3.695064425

3.745739952

Transcription/Chromatin

Ints10

3.643650335

3.093098781

Integrator

Nr1i3

3.613074152

2.71697009

Nuclear Receptor

Rad21

3.595937009

3.99888251

Cohesin

Taf5

3.572662628

3.097665381

Transcription/Chromatin

Zbtb20

3.566321733

4.777392769

Transcription/Chromatin

Mbd3

3.516054008

4.872701732

NuRD/CoREST

Ints2

3.495483998

2.627051313

Integrator

Actl6a

3.494413181

4.633919172

SWI/SNF

Adnp

3.440742452

2.941966284

Transcription/Chromatin

Rprd1b

3.427474467

2.537990764

Transcription/Chromatin

Mta2

3.398119667

5.186276503

NuRD

Wapal

3.38941112

3.458735088

Cohesin

Pds5a

3.343777681

6.188849929

Cohesin

Nmnat1

3.340365082

2.510994062

Supt16h

3.334988721

3.01811442

Srbd1

3.329650536

3.39736468

Ruvbl1

3.329049763

6.021428559
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SWI/SNF

Transcription/Chromatin

Table 3.2 List of primers used for quantitative RT-PCR, ChIP-reChIP-qPCR, and luciferase
experiments.

Type

5' Primer

Arbp
G0s2
Elovl6
Acacb
Gpd1
Cidec
Mfsd2a
Ins
Arbp
G0s2

Target

qPCR
qPCR
qPCR
qPCR
qPCR
qPCR
qPCR
reChIP
reChIP
reChIP

GGCACCGAGGCAACAGTT
CACACTGCCCAGAACGTATAG
AGCATGTAAGCACCAGTTCG
CCGAGTTTGTCACTCGGTTT
TTCCGCTTGTCTCCGTTG
TTGCGAACCTTCCGATCTG
AGGCACAAACCAGATGAGG
AGGGAGGAGGAAAGCAGAAC
AGCAGCTGGCACCTAAACAG
CACGCACAGACACAGACCTT

Elovl6
Agpat2
Gpd1
Mfsd2a
pGL4
G0s2
enhancer
(-17kb)
pGL4
G0s2
enhancer
(-1.7kb)
G0s2 (17kb)
HNF4
DR1
Delta
G0s2 (17kb)
HNF4
DR1
Scramble

reChIP
reChIP
reChIP
reChIP
Gibson
Cloning

TCATCCAGCAGGTGTTTGACA
AAGCCAGTCTGACGCAAG
CAAGCGAGCCAAGTTTGAAC
GATGGAGCGCATACACTTGA
CACAGCATTCTCCAACACAAG
CCAACACAATCCAACTGACAAG
ATTGGATGTGGCTAAGGTGG
CTTCAGCCCAGTTGACCAAT
CTGGGACGATGAATGAGGAT
GGACAAAGTCTACAACCAATCC
A
GGCGTTCAAGGACTGACCTA
ACTCTGCGGGCCTGTACTAA
CATTGGTGACACTCCCCTCT
GGCAGAATGGACTGGTCACT
CGGTACCTGAGCTCGCTAGCCT
CGAGGGGGATTTTGTGGACTT
GAA

Gibson
Cloning

CGGTACCTGAGCTCGCTAGCCT
CGAGAAAGAGGTAGGCCAAAG
GGC

TTATATACCCTCTAGTGTCTAAG
CTTGTGATCAGCACCTTCTGAG
TCT

gBlock
for
Gibson
Cloning

GGGGATTTTGTGGACTTGAACCTAGGGATGACGGAGTATGCAACC
AATCCAACTCACTAATGGGGCACCAGCCAAAATCAACAACTTGCAA
CAGGGGAGAGGCAAAGGTCTGTGTCTGTGCGTGCATCTGTATTCA
CGTGTTTTAAGAACAGTGCACGTTCAAGATGGTGTAACCCACCTTG
GT
GGGGATTTTGTGGACTTGAACCTAGGGATGACGGAGTATGATAGC
GTTCAAGTTGCCAACCAATCCAACTCACTAATGGGGCACCAGCCAA
AATCAACAACTTGCAACAGGGGAGAGGCAAAGGTCTGTGTCTGTG
CGTGCATCTGTATTCACGTGTTTTAAGAACAGTGCACGTTCAAGAT
GGTGTAACCCACCTTGGT

gBlock
for
Gibson
Cloning

3' Primer
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TGATGAAATTGCCTGACAGC
CTGCTTCTCAACTGCCTTGG
TCCAGTGCTGCACCTTGAC
CCTGTAATATGTCTGGGGAGGA
TTATATACCCTCTAGTGTCTAAG
CTTACCAAGGTGGGTTACACC
AT

CHAPTER 4: Generating epitope tagged mouse models using CRISPR-Cas9

The text, figures, and legends in this chapter were the work of Jarrett Renn Remsberg
with the following exceptions. Microinjections were performed by the Transgenic and
Chimeric Mouse Facility. Daniel Cohen assisted in Cas9 synthesis. Jorge Henao-Mejia
provided reagents and technical assistance. Wesley Ho and Marine Adlanmerini provided
mouse husbandry and technical assistance.
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4.1 ABSTRACT
Recent advances in high throughput sequencing and –omic technologies have greatly advanced
our understanding of biological processes and their molecular mechanisms. However, we are still
limited by the constraints of consistent, useful, and available reagents such as antibodies and
viruses. To overcome these constraints, we have employed genome editing techniques to generate
mouse models encoding epitope tag sequences into the endogenous loci for proteins of interest.
Preliminary investigations include the generation of nuclear receptor and corepressor epitope
tagged lines thyroid hormone receptor β1, Rev-erb, and the nuclear receptor corepressor 1
(NCOR1). These mouse models provide an opportunity to interrogate protein-protein interactions
in vivo and will be a significant resource of understanding target protein function in a larger context
of organismal metabolism.

4.2 INTRODUCTION
Genome editing has traditionally been a challenging process, but recent advances have led to a
revolution. The advent of CRISPR-Cas9 technology has given scientists new opportunities in
molecular biology not seen since the wave of siRNA technology in decades previous. As part of
the bacterial innate immune system, CRISPR (clustered regularly interspaced short palindromic
repeats) are part of the bacterial innate immune system, a mechanism by which bacteria store
genetic information to fight against viral infections in the future (Barrangou et al., 2007). This
process has been repurposed as an RNA directed DNA editing platform. The RNA direction comes
in the form of a 20 nucleotide ‘guide’ RNA followed by a scaffold that binds the nuclease, Cas9.
This binding and reconigition of a protospacer adjacent motif (PAM) sequence allow Cas9 to
perform its nuclease catalytic activity and thusly generate a double stranded break in the DNA. One
contributing factor to the success of this technique is the simplicity and limited experimental bench
work required to prepare all components necessary for genome editing. Furthermore, this
technology can be applied to a variety of goals in mind, including but not limited to error-prone
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nonhomologous end joining, gene targeting with dCas9 effector mutants, and homology directed
repair for specific genome editing (Jiang and Doudna, 2017).

Using the CRISPR-Cas9 platform to generate a small knockin, such as an epitope tag coding
sequence, only three reagents are required: Cas9 mRNA, sgRNA, and ssDNA homology donor.
This process has been demonstrated to be successful for generation of mice with conditional alleles
(Yang et al., 2013, 2014). Several studies have worked to determine the molecular basis and
mechanism of Cas9 genomic editing at the atomic resolution (Anders et al., 2014; Jinek et al., 2014;
Nishimasu et al., 2014). CRISPR-Cas9 although relatively new in its application to genomic editing
has been well characterized (Jiang and Doudna, 2017; Sander and Joung, 2014). In the execution
of targeted homology directed repair, two design parameters are required. The first is selection of
the 20 nucleotide ‘guide’ sequence used to target Cas9 to the genomic loci, and the second is the
ssDNA homology donor for integration.

4.2a Targeting proteins of interest
Epitope tagged proteins allow for consistency of reagents and overcome antibody limitations that
may exist for proteins of interest. A major advantage of knocking in an epitope tag in the coding
sequence of a gene is that expression is under endogenous regulatory elements. Therefore we
employed CRISPR-Cas9 to generate several epitope tagged mouse models of interest, including
thyroid hormone receptor β1 (TRβ1), Rev-erb, and NCOR1 to study their functions across a
variety of tissues.

The thyroid hormone receptor β1 is critically important nuclear receptors, with significant
importance in human health, serving as its namesake suggests the receptor for thyroid hormone
(Yen, 2001). It also has a rich history interacting with the retinoid X receptor (RXR) nuclear receptor
and recruiting coregulatory complexes to chromatin (Astapova, 2016). There may be distinct roles
for SMRT and NCOR1 in TR mediated repression (Shimizu et al., 2015). Also T3 binding has
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recently been shown to regulate DNA binding of TRβ1 (Grøntved et al., 2015; Ramadoss et al.,
2014). A novel epitope tagged TRβ1 mouse model would allow targeted investigation of the nuclear
receptor paradigm of coregulatory exchange in vivo, in part due to the ability to control the
availability of the endogenous ligand, thyroid hormone.

To compliment the investigation of TRβ1 in vivo, we generated an NCOR1 tagged mouse model.
Whereas the perspective of tagged TRβ1 will inform exchange of coregulator complex recruitment,
a handle on NCOR1 will determine all factors that utilize the corepressor complex. Analogous to
the work already conducted in liver using an epitope tagged HDAC3, an endogenously tagged
NCOR1 will provide a setting to continue interaction studies beyond liver. Furthermore, questions
remain regarding the contributions of NCOR1 vs SMRT in vivo and this reagent aims to address
these differences (Shimizu et al., 2015; Sun et al., 2013).

Finally, Rev-erb expression is a highly regulated at both on the mRNA and protein levels. As a
member of the core molecular clock machinery, it oscillates in expression with a period of
approximately 24 hours (Papazyan et al., 2016b). Expression is greatest at approximately ZT10
(Zeitgeber time, ZT; where ZT0 is ‘lights on’ and ZT12 is ‘lights off’) and troughs at ZT22. Such
dynamic regulation suggests possible post-translational modifications, and indeed phosphorylation
plays an important role in its stability (Yin et al., 2006). Interestingly, it has also been shown to
regulate gene transcription through indirect binding of DNA, but the precise mechanism and
interactors are yet to be understood (Zhang et al., 2015). Also, an epitope tag at the endogenous
locus presents a rare opportunity to address the protein-protein interactions in a circadian manner
for Rev-erb, as the tagged protein will be under the same endogenous regulatory elements and
ideally controlled in the same manner.
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4.3 METHODS
4.3a Design guidelines
The online tool, crispr.mit.edu was used to determine potential guide sequences for targeting. The
DNA sequence surrounding the locus of interest (+/- 100bp) was used, and guide sequences with
their off target sites were compared. In all cases, the sgRNA would target the double stranded cut
within approximately 15 bases of the desired insertion site. If multiple guides were available, the
one with the least off target hits and highest score was chosen.

4.3b Cas9 mRNA and sgRNA production
To generate Cas9 mRNA, plasmid containing Cas9-HA-2NLS was linearized with XbaI.
Approximately 1g of linearized plasmid was incubated with HiScribeTM T7 Quick High Yeild RNA
Synthesis kit (NEB #E2050S). RNA was purified using RNeasy mini columns (Qiagen #74106).
Capping reaction used Vaccinia Capping System (NEB #M2080S). RNA was purified using RNeasy
Micro clean up column (Qiagen #74004). Capped Cas9 mRNA was then subject to polyadenylation
(NEB #M0276S) and purified over RNeasy Micro clean up column and eluted in RNase-free water.
Cas9 mRNA integrity was validated using RNA BioAnalyzer. T7 promoter was added onto gRNA
template by PCR amplification using specific primers. The T7-sgRNA product was purified using a
PCR purification kit (Qiagen) and used as the template for in vitro transcription using the
MegaShortScript kit (Life Technologies) following the manufacturer’s instructions. Subsequent
sgRNA was purified using the MegaClear Kit (Life Technologies) and verified by RNA BioAnalyzer
before dilution for microinjection.

4.3c Microinjection of zygotes
Microinjection was performed by the transgenic mouse facility at UPenn. Microinjection buffer
consisted of 1mM Tris pH 8.0, 0.1mM EDTA, 100ng/uL Cas9 mRNA, 50ng/uL sgRNA, and
100ng/uL of ssDNA homology donor.
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4.3d PCR genotyping and sequencing
PCR primers flanking the site of insertion were designed using primer3. Edited mice were
genotyped by PCR amplification products. Bands of the approximate correct size were gel
extracted and sequenced using the same PCR primers (Table 4.1).

4.3e Immunoprecipitation and western blotting
For western blot analysis of total lysates, samples were lysed in a TissueLyser (Qiagen) in
radioimmunoprecipitation assay buffer (RIPA buffer) supplemented with Complete EDTA-free
protease inhibitor (Roche) and 1 mM PMSF. Proteins were precipitated in 2.5 volumes ice cold
acetone and washed with 1mL ice cold acetone before being resuspended in RIPA buffer and
subject to Bradford assay. Samples were resolved by Tris-glycine SDS-PAGE (Biorad), transferred
to nitrocellulose membrane (Biorad), and blotted with the indicated antibodies. Antibodies for
western blotting were anti-HA 3F10 High Affinity (Roche, 12013819001) and anti-Actin (Santa Cruz,
sc-1616). For immunoprecipitation followed by western blot livers were lysed in RIPA buffer
containing protease inhibitors and PMSF. Samples were pre-cleared with protein A sepharose CL4B (GE Healthcare), and incubated with anti-HA agarose (Sigma, A2095). Immunoprecipitates
were washed 5 times with RIPA and eluted with SDS loading dye.

4.3f ChIP-qPCR
ChIP-qPCR were as described previously (Feng et al., 2011; Lim et al., 2015). Briefly, livers were
mildly dissociated by dounce with pestle A for 6 strokes in PBS containing 1% formaldehyde and
rocked for 15 min, quenched with glycine, washed with PBS, and sonicated with a probe-type
sonifier (Branson) in RIPA supplemented with protease inhibitors and PMSF. Sonicated extracts
were immunoprecipitated with anti-HA agarose (Sigma, A2095) and isolated DNA was subject to
RT-qPCR (Table 4.1).
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4.3g Mass spectrometry
Livers were dounced in 1mL of RIPA buffer for 10 strokes and sonicated at 10 and 15W for 10
seconds. Extracts were cleared by centrifugation and were immunoprecipitated with anti-HA
agarose (Sigma, A2095) overnight, washed 3 times in RIPA supplemented with protease inhibitors
and 1 mM PMSF, washed 2 times in RIPA, washed 2 times in HPLC-grade water, eluted with 10%
ammonium hydroxide diluted in HPLC-grade water, and dried to completion in a SpeedVac
(Eppendorf).

Samples were prepared for MS as previously described (Armour et al., 2013). After
reduction/alkylation, samples were digested with LysC (Wako) for 2 hours followed by Trypsin
(Promega) at 37°C overnight. Samples were resuspended in 1% acetic acid, and desalted with C18
stage tips, as previously described (Rappsilber et al., 2003). EASY-nanoLC (Thermo Fisher
Scientific) was configured with a 75 µm ID x 17 cm Reprosil-Pur C18-AQ (3 µm; Dr. Maisch GmbH,
Germany) nano-column and coupled with an Orbitrap Fusion mass spectrometer (Thermo Fisher
Scientific). Full scan MS spectrum (m/z 360−1600) was performed in the Orbitrap with a resolution
of 120,000 (at 200 m/z). Fragmentation was performed with higher-energy collisional dissociation
(HCD) and a maximum injection time of 120 msec. MS/MS data were collected in centroid mode in
the ion trap mass analyzer. Peptides were identified using MaxQuant (v1.5.3.30) using the Mus
Musculus UniProt FASTA database (March 2016) with an FDR<1% at the peptide spectrum match
and protein levels.

4.4 RESULTS
4.4a Designing targeting sequence for CRISPR/Cas9 targeted knockin
The CRISPR-Cas9 system is an elegant means to generate site specific double stranded breaks
(DSBs) since the targeting is accomplished by the guide RNA (sgRNA). The sgRNA, Cas9 protein,
and target DNA form a ternary complex, and recognition of the PAM sequence allows Cas9 to
perform catalysis (Figure 4.1A). There are two guiding principles in the design and selection of
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sgRNA sequences to generate a successful knockin, minimizing potential off target editing and
proximity to insertion site for efficient homology directed repair. We used the publically available
crispr.mit.edu to identify potential guide sequences and subsequent off target sites for a given
locus. Epitope tags are traditionally placed on the amino (N-) or carboxy (C-) terminus of the protein
as to minimize interference with folding and function. A key feature of N-terminally tagged insertions
is to place the epitope immediately after the start codon, methionine. Placing the tag prior to the
endogenous methionine and creating Met-tag-Met-CDS could result in translation skips and thus
protein products that lack the tag. For consideration of the cut site, the sgRNA-Cas9 complexed
with DNA generates the DSB 3 bases prior to the end of the target guide sequence. With these
principles in mind, a guide sequence meeting all the criteria was chosen (Figure 4.1B). For
example, the guide chosen for the insertion of a tag at the N-terminus of Rev-erb generates a
DSB closest to the start codon and has the highest score from the algorithm. This score takes into
account possible off target editing events based on mismatches in the guide sequence elsewhere
in the genome. In the case for Rev-erb, this highest scoring guide had 141 possible off target
sites, 16 of which are in genes and 15 of those are exonic, all with at least 2 mismatches.

4.4b Confirming genome editing by PCR and Sanger sequencing
To determine if successful genome editing occurred, we PCR amplified the target locus with
primers flanking the region. If a successful insertion occurred we observed a corresponding
increase in the amplicon after PCR, 57 bases for the 6-His-HA tag, and 93 bases for the 3xHA tag.
Products with increased size were subject to extraction and Sanger sequencing to confirm if the
insertion produced the desired editing and no mutations arose (Figure 4.2A-C). Sequencing is
crucial to determine those editing events where homologous recombination correctly integrated the
ssDNA homology donor versus those that did not. In addition, it is valuable to sequence verify
offspring from the founder to ensure the desired editing incorporated into the germ line as founders
can be mosaic (data not shown for 3xHA-Rev-erb).
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4.4c Validating epitope tagged proteins in vivo
With successful genome editing and introduction of the epitope tag sequence, we next determined
if proteins of interest were translated with the epitope tag and if this epitope was functional as a
molecular handle. Immuniprecipitation followed by western blot analysis from whole cell liver
lysates addressed two questions, first if the tagged protein was expressed, and second if the
epitope was able to pull the target protein down. We detected 6His-HA-TRβ1 and enriched for the
protein using anti-HA agarose (Figure 4.3A). Another feature of multiple proteins with the same
epitope tag allows for valid comparisons using the same antibody, previously unachievable with
antibodies against endogenous proteins that have varying binding affinity. Western blot analysis of
whole cell lysates liver from 6His-HA-TRβ1 and 6His-HA-NCOR1 mice demonstrates that TRβ1 is
expressed vastly less than NCOR1 (data not shown).

Additionally, as with TRβ1, we successfully immunoprecipitate tagged NCOR1 (Figure 4.4A).
However, in addition to full length NCOR1, we observe a number of bands clearly evident in input
and after immunoprecipitation. Full length NCOR1 is a very large protein (2454 amino acids), but it
can have a variety of splice variants and isoforms. As a result of this epitope tag being inserted at
the beginning of the coding sequence for NCOR1, we are likely observing the various splice
variants of NCOR1, or possible degradation products. To confirm full length and functional NCOR1
is generated, liver from 6His-HA-NCOR1 mice was subjected to immunoprecipitation followed by
nano-liquid chromatography coupled to mass spectrometry. We identified unique peptides
spanning the full length of NCOR1, suggesting transcripts containing the epitope tag are
successfully translated into the full length construct (Figure 4.4B). Additionally, we identified
several NCoR complex members including HDAC3, TBL1X, and TBL1XR1 (Figure 4.4C). Further
research is warranted to determine the role these lower molecular weight variants of NCOR1.

With the success of knocking in 57 base pairs of DNA to include a 6-His and HA tag, we sought to
determine if we can achieve proper homologous recombination of a larger tag. Therefore we aimed
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to insert a 3xHA tag, totaling 93 bases into the N-terminus of Rev-erb. To tag Rev-erb, we are
limited to its N-terminus, as the C-terminus overlaps with the thyroid hormone receptor  (Lazar et
al., 1989). Moreover, this is an excellent protein example to study since it is highly regulated, both
at the transcriptional and protein levels. To ensure that the tag did not disrupt protein stability or
regulation, 3xHA-Rev-erb mice were harvested across circadian time points. Similar to the
unmodified Rev-erb, the 3xHA version at 75kDa was expressed highest at ZT10, and was not
detectable at ZT22 (Figure 4.5A). It is unclear if the lower band observed at approximately 55kDa
in ZT10 is a degradation product or truncation and further investigations are warranted. In addition
to the proper regulation of Rev-erb protein abundance, its circadian mRNA expression displayed
a similar pattern and amplitude, as well as Bmal1, a known target gene and circadian clock
component (Figure 4.5B). Further validation of the 3xHA-Rev-erb was conducted by ChIP-qPCR
at known clock target genes (Figure 4.6A).

A significant driver for whole mouse models containing epitope tags in the genome is the ability to
compare across multiple tissues. We previously understood that Rev-erb plays an important role
in multiple metabolic organs beyond liver and this new tool can be applied to address these
functions. Tissue from mice expressing the 3xHA-Rev-erb on both allele were harvested and
subsequently lysed and proteins precipitated. Relatively equivalent total protein was loaded onto
an SDS-PAGE gel (Figure 4.7A). We observed a significant difference in the abundance of 3xHARev-erb across liver, fat depots, and muscle (Figure 4.7B). The detection of 3xHA-Rev-erb also
serves as a launching pad to employ cross-linking immunoprecipitation mass spectrometry
techniques in tissues beyond liver to compare tissue specific interactomes.

4.5 DISCUSSION
We have demonstrated that CRISPR-Cas9 is a simple and effective means for genome editing and
generating novel mouse models. The single cell zygote injection can significantly reduce the time
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to generate these models. It is important to note however, that offspring from the founder mice
should be sequence verified, as the germ line can have variable editing. Also single stranded DNA
homology donor limits the insertion size to approximately 100bp, leaving 50bp of homology on
either arm. We did not explore the effectiveness of larger insertions, such as fluorescent proteins
or regulatory DNA elements such as eRNAs. In the design and execution of genome editing, there
is a constant worry of off target events that could occur. Thankfully, these mouse models are backcrossing to ensure the removal of any deleterious editing in their generation, and therefore the most
efficient guide with the highest likelihood to succeed can be utilized.

We have demonstrated that knocking in epitope tags allows for the detection of the protein of
interest across tissues. Importantly, this can serve to compare relative abundance and expression
levels in those tissues. Approximately equivalent total protein in each lane resulted in dramatically
different levels of 3xHA-Rev-erb as observed by western blot. Interestingly, unlike originally
observed using northern blotting, protein levels of 3xHA-Rev-erb in the soleus muscle are less
than liver (Lazar et al., 1989). Furthermore, a recent study using mass spectrometry aimed to
determine the best loading control across multiple tissues and found DJ-1 to be ideal for brain, liver,
and muscle among others (Wiśniewski, 2017; Wiśniewski and Mann, 2016). It should be noted that
fat depots were not included in their analyses. Indeed both white, but more prominently the brown
fat depot differed greatly in DJ-1 detection compared to liver and muscle where the same total
protein abundance was loaded. Future mass spectrometry proteomic studies would be necessary
to validate these findings and for comparison of protein abundance across tissues using recent
techniques and replicates (Wiśniewski, 2017).

Addition of HA epitope tag has proven useful for detection and immunoprecipitation of target
proteins, as well as comparisons across various tissues. A major driving force for the generation of
these novel mouse models is for applications in tissues other than liver, an organ that can be easily
be manipulated by AAV infection. Also the expression of these tagged proteins is entirely under the
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endogenous regulatory elements, as evident by 3xHA-Rev-erb. Each of the models described
serve a distinct purpose to address unanswered questions in their respective areas of research. In
regard to TRβ1, a protein that is antibody challenged, we plan to investigate one of the major
paradigms in nuclear receptor research. TRβ1 is unique among nuclear receptors due to the ability
to control the presence of its endogenous ligand, T3. Future work will assay the genomic occupancy
and interactors of TRβ1 in the absence (via propylthiouracil) and presence (T3 injections) in vivo,
directly testing the nuclear repressor to coactivator switch by ligand binding. The tagged NCOR1
mouse model will be paramount to continue our work from the HDAC3 liver interactome. We
hypothesize that nuclear receptors and DNA binding factors, expressed in a tissue specific manner
utilize the NCoR complex to repress their target gene program. This will be investigated by
comparing the liver interactome to other tissues such as white and brown fat depots, where other
work in the lab has demonstrated NCoR complex members are critical. Finally, the 3xHA-Rev-erb
mouse model presents unique opportunities to study, in part to determine interactome as a function
of time, sampling across circadian time points.
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Figure 4.1 CRISPR-Cas9 genome editing. (A) Crystal structure of Cas9 in a ternary complex with
sgRNA and the target DNA (PDB 4UN3). (B) Targeting the start codon of Rev-erb to insert an Nterminal epitope tag.
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Figure 4.2 Sanger sequencing confirmation of targeted genome editing. (A) 3xHA sequence
knocked into the Rev-erb CDS locus. (B) 6-His-HA sequence knocked into the TRβ1 CDS locus.
(C) 6-His-HA sequence knocked into the NCOR1 CDS locus.
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Figure 4.3 Validation and immunoprecipitation western blot of 6-His-HA-TRβ1. (A) Liver from
wild-type (WT) control or mice expressing 6-His-HA-TRβ1 on both alleles were lysed and subject
to IP-WB using anti-HA agarose and anti-HA-HRP. Non-specific band is denoted by *.
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Figure 4.4 Validation of 6-His-HA-NCOR1 by immunoprecipitation western blot and mass
spectrometry. (A) Liver from wild-type (WT) control or mice expressing 6-His-HA-NCOR1 on both
alleles were lysed and subject to IP-WB using anti-HA agarose and anti-HA-HRP. (B) Graph
denoting the unique peptides identified from IP-MS of 6-His-HA-NCOR1. (C) Identification and
coverage of NcoR complex members from IP-MS of 6-His-HA-NCOR1.
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Figure 4.5 Circadian expression of 3xHA-Rev-erb. (A) Western blot of mice expressing 3xHARev-erb (band at 75kD) on both alleles across 24 hour cycle in liver. Actin protein levels are shown
as loading control. (B) Quantitative RT-PCR in liver of homozygous 3xHA-Rev-erb and wild-type
mice (n=1-3, ZT time points are repeated).
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Figure 4.6 Validation of 3xHA-Rev-erb binding to known target genes. (A) ChIP-qPCR of
heterozygous 3xHA-Rev-erb at known clock target genes (n=1).
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Figure 4.7 Comparison of Rev-erb protein abundance across tissues. (A) Ponceau staining
of western blot. Each lane was loaded with 25g of total protein. (B) Western blot against 3xHARev-erb at ZT10 and ZT4 in metabolic tissues. DJ-1 is shown as a potential loading control.
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Table 4.1 List of primers used for quantitative RT-PCR, ChIP-qPCR, and genotyping.

Target

Type

5' Primer

3' Primer

Arbp
Nr1d1
Bmal1
Ins
Arbp
Npas2
Bmal1
Ncor1

qPCR
qPCR
qPCR
ChIP
ChIP
ChIP
ChIP
Genotyping
Genotyping
Genotyping
Guide
sequence
Guide
sequence
Guide
sequence

TCATCCAGCAGGTGTTTGACA
GTCTCTCCGTTGGCATGTCT
TAGGATGTGACCGAGGGAAG
CTTCAGCCCAGTTGACCAAT
CTGGGACGATGAATGAGGAT
TTGCAGAAGCTTGGGAAAAG
AGCGGATTGGTCGGAAAGT
ACACACACACACACACATCTTG

GGCACCGAGGCAACAGTT
CCAAGTTCATGGCGCTCT
TCAAACAAGCTCTGGCCAAT
AGGGAGGAGGAAAGCAGAAC
AGCAGCTGGCACCTAAACAG
TTTCCTGTGGGAGGAGACAG
ACCTCCGTCCCTGACCTACT
GCTTTGCCTGGAAATTGTGGT

TAAGCCTTGGATGGAAATGG

AGCCACCCCAAGACCTTACT

CTCTGTGAGTTTGAAGAAAGC

TCAGGTTGGCTTTAGAACCCC

Reverb
TRβ1
Ncor1
Reverb
TRβ1

TTACTGATAATGTCAAGTTC
TGGTGAAGACATGACGACCC
GTCATACTGTTAGGAGTCAT
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CHAPTER 5: Summary and Future Directions
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5.1 SUMMARY
This work encompasses significant advances in our understanding of HDAC3 function in
mammalian physiology and gene regulation. Utilizing mouse genetic models, we determined this
epigenomic regulator plays a critical role in adult mouse β-cells. Interestingly, these findings
suggest that ablation of HDAC3 in the β-cells could be beneficial for diet induced obesity as the
body struggles to maintain glucose homeostasis. Indeed, another recent study suggests
pharmacologic inhibition of HDAC3 has beneficial effects on glucose homeostasis in a diabetic rat
model (Lundh et al., 2015). Physiologic measurements showcase HDAC3’s important role in
glucose-stimulated insulin secretion, whereas transcriptome and cistromic analysis hinted at
possible molecular mechanisms. The potentiation of glucose-stimulated insulin secretion as a
result of dysregulation of HDAC3 target genes remains to be more clearly understood, but we can
speculate from the altered transcriptome. One hypothesis that emerges is that increased bile acid
transport potentiates glucose-stimulated insulin secretion in the HDAC3βKO mice. Two organic
anion transporters are significantly upregulated with ablation of HDAC3. To test this hypothesis and
better understand the kinetics of insulin secretion in the β-cell knockout of HDAC3, perfusion
experiments would be highly informative. These allow the direct measurements of β-cell function
over time while controlling the system, modulating the buffer the isolated islets are exposed to, and
measuring the resulting output.

Furthermore, we dove into the molecular underpinnings of HDAC3 mediated repression in
mammalian liver by combining mass spectrometry and cistromic analyses. This work identified a
variety of nuclear receptors and DNA binding proteins that associate with the NcoR complex in
liver. Indeed, this workflow could be adapted to other proteins of interest that are within the size
limitation of the AAV8 vector or epitope tagged mouse model. Importantly, we identified a previously
unknown complex involved in the regulation of lipid-related genes in liver, where HNF4 recruits
both the NCoR complex and PROX1 to repress target genes. Integration of cistromic data proved
extremely valuable to segregate potential interactors as well. This is highlighted in the comparison
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of PROX1 specific, HDAC3 specific, and co-bound peaks, which suggests that HDAC3 and PROX1
are recruited in conjunction by HNF4, however only HDAC3 is recruited to Rev-erb sites.
Disecting the data in this fashion is important because when we observe interactomes and mass
spectrometry data, they are an ensemble of all HDAC3 interactions and we cannot parse which
interactors are present with one another. Although, reciprocal interactomes from other proteins
could build a more complete network, those experiments are laborious and may not be informative
unless some interactors are uniquely identified. Instead, we gained valuable insight from the
cistromic data by understanding where along the genome these distinct complexes bind and their
potential target genes.

Two directions that can extend our understanding of these chromatin associated complexes are
both related to mass spectrometry technologies, one being cross-linking mass spectrometry for the
identification of peptide-peptide cross links. Understanding the organization and competition of coregulators may inform as to how these proteins control gene expression. Combination of traditional
structural studies such as cyro-electron microscopy, crystallography, and cross-linking mass
spectrometry allow for a more complete picture of large protein complexes. The other and more
challenging would be locus specific interrogation of protein-protein interactions. To determine with
confidence the DNA binding factors and coregulators present at a given genomic locus would be
extremely valuable (Wierer and Mann, 2016). Unfortunately, there is no PCR for proteins, and mass
spectrometry techniques are limited in detection. Advances in technology has significantly
decreased the minimum number of molecules for detection, but it is still on the order of fmol, or 1e8
molecules, a major challenge for locus specific interrogation.
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5.2 FUTURE DIRECTIONS
5.3a Tissue specific interactomes
Generating novel epitope tagged mouse models presents a unique opportunity. Where before we
were limited to liver for expression of epitope tagged constructs, by having this encoded in the
genome of the animal itself, we can compare different tissues. This is especially exciting for two of
the CRISPR-Cas9 generated mouse models, Rev-erb and NCOR1. For the case of Rev-erb, we
understand it has important roles in multiple metabolic organs such as liver and brown fat, and in
liver in particular research shows that other DNA binding proteins may play a critical part in the
tethering of Rev-erb to chromatin. Using this model we can empirically determine those proteins
that interact and recruit Rev-erb to chromatin in liver, and identify if there are others in brown fat.
The epitope tagged NCOR1 presents a very unique opportunity for continued investigation of the
NCoR complex in vivo, namely to determine the tissue specific nuclear receptors and DNA binding
proteins that utilize the NCoR complex to repress their target gene program (Figure 5.1A).

Another dimension to investigate protein-protein interactions is across circadian time points, and
the best example of this is the 3xHA-Rev-erb mouse model we developed. This specific protein
is especially interesting due to its highly regulated expression levels. Future work will investigate if
there are circadian specific interactions or modifications on 3xHA-Rev-erb that are critical for its
function in mammalian liver (Figure 5.1B).

5.3b Cross-linking mass spectrometry
The past several years has seen the expansion and widespread use of cross-linking mass
spectrometry following two major themes. The first is exploited by our own work, mirroring
chromatin immunoprecipitation for the capture and identification of DNA binding proteins and lower
affinity/transit interactors by formaldehyde cross-linking. The second, more challenging yet more
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informative method is that of using cross-linkers to determine peptide-peptide cross-links of
proteins in complex. This technology recently overcame a major hurdle in the form of CID (collision
induced dissociation) inducible cross-linkers, such as disuccinimidyl sulfoxide (DSSO) (Figure
5.2A). Previously, identification of peptide-peptide cross-links was a monumental challenge due to
the complex MS2 spectra and subsequent database searching which increased n^2. The advent
of CID cleavable cross-linkers allows users to simplify the complex spectral searching to standard
searches including the cleaved cross-linker, substantially decreasing computation time and
allowing for more complex samples (Figure 5.2B). However, this requires an MS3 event and
benefits from more high resolution mass spectrometers. Multiple studies have proven that cellular
complexity is no longer an unsurmountable obstacle for cross-linking mass spectrometry (Chavez
et al., 2011, 2016; Schweppe et al., 2017; Wang et al., 2017; Weisbrod et al., 2013; Wu et al., 2016;
Zhong et al., 2017). Applying this technique to better understand the organization and direct
protein-protein interactions of the NCoR complex on chromatin would be invaluable.
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Figure 5.1 Future directions to interrogate interactomes in vivo. (A) Schematic plan to
compare tissue specific interactomes of CRISPR-Cas9 generated epitope tagged mouse models.
(B) Diagram demonstrating circadian dependent interactome of 3xHA-Rev-erb.
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Figure 5.2 CID cleavable cross-linker to identify peptide-peptide cross-links in complex
mixtures. (A) Graphic detailing the CID cleavable cross-linker, DSSO reaction with peptides
containing lysine primary amines (dashed lines represent bonds that are cleavable). (B) Schematic
representation of MSn allowing for traditional analysis of spectra for peptide sequence identification
from cross-linked peptides.
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